University of Kentucky

UKnowledge
Theses and Dissertations--Neuroscience

Neuroscience

2011

NIGROSTRIATAL DOPAMINE-NEURON FUNCTION FROM
NEUROTROPHIC-LIKE PEPTIDE TREATMENT AND
NEUROTROPHIC FACTOR DEPLETION
Ofelia Meagan Littrell
University of Kentucky, omlittrell@gmail.com

Right click to open a feedback form in a new tab to let us know how this document benefits you.

Recommended Citation
Littrell, Ofelia Meagan, "NIGROSTRIATAL DOPAMINE-NEURON FUNCTION FROM NEUROTROPHIC-LIKE
PEPTIDE TREATMENT AND NEUROTROPHIC FACTOR DEPLETION" (2011). Theses and Dissertations-Neuroscience. 1.
https://uknowledge.uky.edu/neurobio_etds/1

This Doctoral Dissertation is brought to you for free and open access by the Neuroscience at UKnowledge. It has
been accepted for inclusion in Theses and Dissertations--Neuroscience by an authorized administrator of
UKnowledge. For more information, please contact UKnowledge@lsv.uky.edu.

STUDENT AGREEMENT:
I represent that my thesis or dissertation and abstract are my original work. Proper attribution
has been given to all outside sources. I understand that I am solely responsible for obtaining
any needed copyright permissions. I have obtained and attached hereto needed written
permission statements(s) from the owner(s) of each third-party copyrighted matter to be
included in my work, allowing electronic distribution (if such use is not permitted by the fair use
doctrine).
I hereby grant to The University of Kentucky and its agents the non-exclusive license to archive
and make accessible my work in whole or in part in all forms of media, now or hereafter known.
I agree that the document mentioned above may be made available immediately for worldwide
access unless a preapproved embargo applies.
I retain all other ownership rights to the copyright of my work. I also retain the right to use in
future works (such as articles or books) all or part of my work. I understand that I am free to
register the copyright to my work.
REVIEW, APPROVAL AND ACCEPTANCE
The document mentioned above has been reviewed and accepted by the student’s advisor, on
behalf of the advisory committee, and by the Director of Graduate Studies (DGS), on behalf of
the program; we verify that this is the final, approved version of the student’s dissertation
including all changes required by the advisory committee. The undersigned agree to abide by
the statements above.
Ofelia Meagan Littrell, Student
Dr. Greg A. Gerhardt, Major Professor
Dr. Wayne A. Cass, Director of Graduate Studies

NIGROSTRIATAL DOPAMINE-NEURON FUNCTION FROM NEUROTROPHIC-LIKE
PEPTIDE TREATMENT AND NEUROTROPHIC FACTOR DEPLETION

______________________________________________
DISSERTATION
______________________________________________
A dissertation submitted in partial fulfillment of the
requirements for the degree of Doctor of Philosophy in the
College of Medicine
at the University of Kentucky

By
Ofelia Meagan Littrell
Lexington, Kentucky
Director: Dr. Greg A. Gerhardt, Professor of Anatomy and Neurobiology
Lexington, KY
2011
Copyright © Ofelia Meagan Littrell

ABSTRACT OF DISSERTATION

NIGROSTRIATAL DOPAMINE-NEURON FUNCTION FROM NEUROTROPHIC-LIKE
PEPTIDE TREATMENT AND NEUROTROPHIC FACTOR DEPLETION
Trophic factors have shown great promise in their potential to treat neurological
disease. In particular, glial cell line-derived neurotrophic factor (GDNF) has been
identified as a potent neurotrophic factor for midbrain dopamine (DA) neurons in the
substantia nigra (SN), which lose function in Parkinson’s disease (PD). GDNF
progressed to phase II clinical trials, which did not meet proposed endpoints. The large
size and binding characteristics of GDNF have been suspected to contribute to some of
the shortcomings of GDNF related to delivery to target brain regions. Smaller peptides
derived from GDNF (Dopamine-Neuron Stimulating Peptides – DNSPs) have been
recently investigated and appear to demonstrate trophic-like effects comparable to
GDNF. In the described studies, a time course study was conducted to determine in vivo
DA-release characteristics 1-, 2- and 4- weeks after peptide treatment. These studies
determined the effects on DA terminals within striatal sub-regions using microelectrodes.
A heterogeneous effect on striatal sub-regions was apparent with the maximum effect in
the dorsal striatum – corresponding to terminals originating from the SN.
Dysregulation of GDNF or GDNF signaling is believed to contribute to motor
dysfunction in aging and PD. Thus, it is hypothesized that GDNF is necessary for the
maintenance and function of neurons. To extend this line of investigation, in vivo
functional measures (DA-release and -uptake) and behavioral and cellular alterations
were investigated in a transgenic mouse model (Gdnf+/-) with reduced GDNF protein
levels. The described studies determined that both DA-uptake and -release properties
were altered in middle-aged Gdnf+/- mice with only modest reductions in DA
neurochemical levels. GDNF levels in Gdnf+/- mice were restored to levels comparable to
wild-type (WT) counterparts by treatment with GDNF. GDNF protein supplementation led
to enhanced motor behavior and increased markers for DA neurons in the SN of Gdnf+/mice. Gdnf+/- mice appeared to show a heightened sensitivity to GDNF treatment
compared to WT counterparts.
Overall, this body of work examines novel synthetic peptides with potential to
enhance DA-neuron function and expands upon the current understanding of GDNF’s
role in the nigrostriatal pathway.

KEYWORDS: glial cell line-derived neurotrophic factor,
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Chapter One: Introduction

Dopamine
Dopamine

(DA)

was

first

suggested

to

function

as

an

independent

neurotransmitter by Arvid Carlsson (Carlsson, 1959). Carlsson described distinct
catecholamine distribution patterns that challenged the existing dogma that DA served
exclusively as a metabolic intermediate in the synthesis of norepinephrine and
epinephrine. Since the relatively recent acceptance of DA as a chemical messenger in
the brain, several DA nuclei have been identified and examined for physiological
significance. Indeed, the involvement of DA in reinforcement and reward pathways has
led to intense investigation regarding substances of abuse (Sulzer, 2011) as well as
other psychiatric disorders like bipolar disorder (Cousins, et al., 2009), schizophrenia
(Hirvonen and Hietala, 2011) and attention-deficit hyperactivity disorder (Swanson, et al.,
2007).
Arguably, the most widely studied area of neuroscience concerning DA
neurotransmission has been its role in motor function within the basal ganglia –
specifically concerning the marked loss of functional DA neurons seen in Parkinson’s
disease (PD) (Bernheimer, et al., 1973). The nigrostriatal pathway is comprised of DAneuron projections that originate from the midbrain DA nucleus, the substantia nigra
(SN), and terminate in the caudate/putamen (striatum). The following studies will focus
on the cellular and functional characteristics of DA neurons within the nigrostriatal
pathway and associations with motor function in rodent models.

Dopamine Neurotransmission
Synthesis, Storage and Release
Fundamental aspects of DA neurotransmission are depicted in a simplified DA
synapse (Figure 1.1). In the presynaptic DA neuron, DA is synthesized from the amino
acid tyrosine. Tyrosine is converted to levodopa ((L-3,4-dihydroxyphenylalanine; LDOPA) in the rate-limiting reaction catalyzed by tyrosine hydroxylase (TH) using a
tetrahydrobiopterin (BH4) co-factor and O2. Levodopa is converted to DA by aromatic Lamino-acid decarboxylase (AAADC) (Hornykiewicz, 1966). Presynaptic DA may be
packaged into acidic vesicles using proton co-transport by the vesicular monoamine
transporter (VMAT-2) (Cooper, et al., 2003; Flatmark and Stevens, 1999; Kanner and
1

Schuldiner, 1987). For most considerations in this dissertation, the term “DA release” is
used in reference to depolarization-induced vesicular exocytosis of DA, a Ca++dependent release process (Cooper, et al., 2003; Grace and Bunney, 1984a), which is a
stimulated release event comparable to “phasic” DA release (Goto, et al., 2007).
Additionally, single-spike firing activity of DA neurons, also Ca++-dependent, contributes
to DA release often referred to as “tonic” DA release (Floresco, et al., 2003; Goto, et al.,
2007; Grace and Bunney, 1984b). Both tonic and phasic DA release are relevant to the
discussion of DA depletion in PD and related dysfunction of the nigrostriatal pathway
(Obeso, et al., 1994). While phasic and tonic DA release are perhaps the most relevant
release mechanisms under physiological conditions, carrier-mediated release (Ca++independent) is another source of increased extracellular DA concentrations (Hurd and
Ungerstedt, 1989) used in the described experiments.
Dopamine release, of any mechanism, may be influenced by numerous factors
including: the readily releasable pool of DA in the synapse, number/size of vesicles, DAterminal density and other synthesis- and release-modulating factors (Bark and Wilson,
1994; Gerhardt, et al., 1986; Gillis, et al., 1996; McMillen, et al., 1980; Pothos, et al.,
2000; Rosenmund and Stevens, 1996; Santiago and Westerink, 1991; Shui, et al., 1998;
Sulzer and Pothos, 2000). Although these aspects of DA-neuron function are relevant in
the subsequent studies of DA release and neurochemical changes, a comprehensive
treatment of these mechanisms and their interactions is beyond the scope of the current
studies. Dopamine-release dynamics are important considerations as the amount of
released DA contributes to the net effect on DA receptors. Another contributing factor to
the net effect of DA is clearance from the extracellular space (Jones, et al., 1998).
Dopamine Clearance – Transport and Metabolism
Along with the quantity of DA released, another major determinant of the net
interaction of DA and DA receptors is the lifetime of DA in the synapse. Because highaffinity uptake by the DA transporter (DAT) is the primary means by which extracellular
DA is removed, the DAT is a significant contributor to termination of DA interaction with
DA receptors (Iverson, 1975). The DAT is present in highest densities in the striatum
(Aquilonius, et al., 1987). Molecular studies indicate there are several sights for
glycosylation or phosphorylation that are potentially modulatory (Li, et al., 2004;
Ramamoorthy, et al., 2010) and 12 hydrophobic stretches – corresponding to putative
transmembrane domains linked by intra- and extra-cellular loops (Giros and Caron,
2

1993). Decreased function of the DAT has been associated with PD (Gainetdinov, et al.,
1997) as well as parkinsonism in aging (Hebert, et al., 1999) – topics discussed further
below (see Aging and Dopamine-Neuron Dysfunction: Parkinson's Disease and
Parkinsonism). Under physiological conditions, the DAT allows for the transport of DA
from the extracellular space to the presynaptic DA terminal (Figure 1.1) (Giros, et al.,
1996; Jones, et al., 1998) via co-transport of Na+ and Cl- (Reith, et al., 1997; Wheeler, et
al., 1993). Under some conditions, pharmacological manipulation or ionic disturbance
may facilitate the reverse transport of DA from the cytosol to the extracellular space
(Seiden, et al., 1993; Sulzer, 2011; Wheeler, et al., 1993).
Although the transport of DA by the DAT is generally considered the primary
means of DA clearance, particularly in brain areas of high DAT density like the striatum
(Aquilonius, et al., 1987; Cass, et al., 1993), enzymatic degradation and dilution of
synaptic DA by diffusion are also considerations regarding DA neurotransmission
(Cooper, et al., 2003). Although both metabolism and diffusion are minor contributors to
DA clearance in the striatum, for the purposes of these studies degradation by
metabolism will be discussed further in order to clarify the possible sources of
metabolites (Cass and Gerhardt, 1995; Cass, et al., 1993).
Metabolism of DA is catalyzed by three primary enzymes: monoamine oxidase
(MAO) and COMT (catechol-o-methyl transferase) (Westerink, 1985) (Figure 1.1). Two
forms of MAO exist (MAO-a and MAO-b) (Schoepp and Azzaro, 1982). The action of
either enzyme results in aldehyde conversion of DA and further processing of the
aldehyde intermediate by aldehyde dehydrogenase (AD) (Knoll and Magyar, 1972). For
the purposes of these studies MAO-a and MAO–b forms should be differentiated
primarily based on their localization in the brain, where MAO-a is primarily intraneuronal
and MAO-b is extraneuronal, although other distinctions exist (Waldmeier, 1987). The
enzyme, COMT, is present extraneuronally (Broch and Fonnum, 1972; Kaplan, et al.,
1979). Extracellular DA may be converted to 3,4-dihydroxyphenylacetic acid (DOPAC)
through the combined actions of MAO-b and AD. Cytosolic (non-vesicularized) DA may
be converted to DOPAC by MAO-a and AD. Cytosolic DOPAC may diffuse to the
extracellular space where it is a substrate for COMT to produce homovanillic acid (HVA)
(Kopin, 1985). Thus, metabolism of DA produces two major metabolites, DOPAC and
HVA, which may be referred to as primarily intracellular and extracellular metabolites,
respectively (Roffler-Tarlov, et al., 1971). A third metabolic product, 3-methoxytyramine
(3-MT) may also be formed from the interaction of COMT with extracellular DA.
3

Although, 3-MT is considered a minor metabolite (Westerink and Spaan, 1982) because
it is readily converted to DOPAC by MAO-b (Kopin, 1985). It is also relevant to clarify
that HVA is the primary metabolite in primates (Sharman, et al., 1967; Sternberg, et al.,
1983) while DOPAC and HVA are present in comparatively equal quantities (Dedek, et
al., 1979) in the rodent brain with a slight preference for DOPAC.

Dopamine Receptors
Extracellular DA may bind to DA receptors present on presynaptic and
postsynaptic targets, which are broadly classified into two families: D1 or D2 (Cooper, et
al., 2003; Kebabian and Calne, 1979; Kebabian and Greengard, 1971; Vallone, et al.,
2000) (Figure 1.1). The two families of DA receptors are based on the stimulatory (D1) or
inhibitory (D2) effect on adenylate cyclase (AC) (Beaulieu and Gainetdinov, 2011).
Additionally, several subdivisions of DA receptors exist based on biochemical, structural
and pharmacological distinctions: D1-class (D1, D5) (Tiberi, et al., 1991), D2-class (D2, D3,
D4) (Vallone, et al., 2000). The stimulatory action on AC following stimulation of D1
receptors (a Gαs/olf family of G-proteins) activates the second messenger cAMP and
protein kinase A (PKA) (Beaulieu and Gainetdinov, 2011). In a simplified and
generalized signaling paradigm, D1-receptor activation leads to DARPP-32 (dopamineand cAMP-regulated phosphoprotein, M(r) 32 kDa) phosphorylation and activation,
Activity of DARPP-32 modulates: ionotropic glutamate and GABA receptors, specific ion
channel sensitivity and protein phosphatase 1 (PP1) (Bateup, et al., 2008; Beaulieu and
Gainetdinov, 2011; Greengard, 2001; Hemmings, et al., 1984; Svenningsson, et al.,
2004). Stimulation of D2-class receptors, which couple to the Gαi/o family of G-proteins,
cause inhibition of AC (Vallone, et al., 2000). Generally, D2-class receptors have the
opposing effect on intracellular signaling processes compared with those outlined for the
D1-class receptors. The D1-class of DA receptors are present, exclusively, on
postsynaptic targets while D2-class receptors may be present both presynaptically
(autoreceptors) and postsynaptically (De Mei, et al., 2009). Presynaptically, D2-class
autoreceptors may modulate numerous aspects of neuron function including synthesis,
release and uptake (Cass and Gerhardt, 1994; De Mei, et al., 2009; Kehr, et al., 1972;
Sibley, 1999; Vallone, et al., 2000).
Following this brief overview of the functional DA synapse, the role of DA in
movement disorders like Parkinson’s disease (PD) and age-associated parkinsonism
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must be addressed in the context of the basal ganglia – the motor initiating and
coordinating centers of the brain (Kandel, et al., 2000).
The Basal Ganglia
In the mammalian brain the major dopaminergic pathways are identified as:
nigrostriatal (A9), mesolimbic and mesocortical (A10), and tuberoinfundibular (A8)
(Cooper, et al., 2003; Dahlstrom and Fuxe, 1964a). Because the focus of these studies
is on the nigrostriatal pathway, its coordinative function with other brain nuclei of the
basal ganglia is described further. Although some components of the basal ganglia have
been associated with cognitive, emotional and other functions (Afifi, 1994; Afifi, 2003),
this section will focus on the nuclei and projections most relevant to motor planning,
initiating and coordinating. For a more comprehensive review of basal ganglia circuitry
see (Albin, et al., 1989; Alexander, et al., 1986; Mink, 2007).
The basal ganglia consist of four subcortical nuclei that are divided into
interconnected sub-structures (depicted schematically; Figure 1.2): the striatum, globus
pallidus (GP), substantia nigra (SN) and subthalamic nucleus (STN). The GP may be
divided into separate anatomical and functional divisions: internal (GPi) and external
(GPe) segments. Similarly, the SN is differentiated into the pars compacta (SNc) and
pars reticulata (SNr) (see The Nigrostriatal Pathway). In primates, the striatum is further
described as two separate nuclei, the caudate nucleus and putamen, divided by the
internal capsule. Because the rodent brain lacks delineation of the caudate nucleus and
putamen, the striatum is the accepted nomenclature (Bentivoglio and Morelli, 2005;
Webster, 1975). The action of DA in the striatum is directed to γ-aminobutyric acid
(GABA)-producing medium spiny neurons (MSNs) (Gerfen, 1992a). Dopamine acts on
D1- and D2-class receptors on MSNs projecting to the GPi/SNr (direct pathway) and GPe
(indirect pathway), respectively. It is likely that this view of DA-receptor class segregation
on MSNs is inaccurate. Rather than restricted expression of only one receptor class on
individual MSNs, there is evidence for co-localization of D1 and D2 receptors with
proportional differences between the two in individual neurons and other mechanistic
differences that contribute to the cellular pathways activated (Waszczak, et al., 1998;
Weiner, et al., 1991). For our purposes, the MSN sub-types will be considered D1- or D2“dominant” types, both GABA producing, which may be distinguished based on
projection targets and specific protein expression: dynorphin and substance p (D1),
enkephalin (D2) (Albin, et al., 1989). In the direct pathway, striatal inhibitory projections
5

are stimulated by DA (D1 dominant) and inhibit the GABAergic projections to the
thalamus from the GPi and SNr. In the indirect pathway, inhibitory projections from the
GPe are active leading to inhibition of excitatory projections from the STN to GPi/SNr
and inactivation of inhibitory projections to the thalamus from the GPi/SNr. Because
thalamic output to motor cortices is increased and decreased through the direct and
indirect pathways, respectively, the net effect of DA (increasing activity in the direct
pathway and decreasing activity of the indirect pathway) is to facilitate glutamatergic
output in the thalamocortical projection (Figure 1.2)

The Nigrostriatal Pathway
The nigrostriatal pathway contains dopaminergic projections originating from the
midbrain DA nucleus – the SN. Dopamine neurons of the SN project anteriorly and
diffusely to the striatum (Lindvall and Bjorklund, 1974; Veening, et al., 1982). The SN is
subdivided into the dense band of pigmented, neuromelanin-containing (Zecca, et al.,
2001), DA-neuron cell bodies (the pars compacta (SNc)) and a more ventral region
containing fibers from the SNc but proportionately fewer DA-neuron cell bodies – the SN
pars reticulata (SNr) (Atherton and Bevan, 2005; Bentivoglio and Morelli, 2005; Francois,
et al., 1987).
The striatum is considered a highly heterogeneous structure for several reasons.
Regarding DA innervation of the striatum, afferents arise from several nuclei including
the SNc (A9) and ventral tegmental area (VTA, A10) (Dahlstrom and Fuxe, 1964b),
which demonstrate distinct innervation patterns and functional characteristics (Cline, et
al., 1995; Fallon, et al., 1978; Langer and Graybiel, 1989; Lindvall and Bjorklund, 1974).
The striatum may also be subdivided into functional components based on innervation
patterns unique to the motor- (dorsolateral), associative- (medial) and limbic-striatum
(ventral), which are innervated by the motor cortices, associative/prefrontal cortices and
limbic structures, respectively (Joel and Weiner, 2000; McGeorge and Faull, 1989). This
functional organization is superimposed on an additional organization of the striatum into
striosomes (patch) and matrix components. Patch and matrix regions are discriminated
by differential patterns of acetylcholinesterase staining, presence of specific peptides
and connections with other brain regions (Gerfen, 1985; Gerfen, 1992b; Gerfen, et al.,
1987a; Gerfen, et al., 1987b).
The primary cell type (~95%) in the striatum is the GABA producing MSN.
Medium spiny neurons, distributed throughout the striatum, give rise to the striatonigral
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(direct pathway) or striatopallidal projections (indirect pathway) (Bentivoglio and Morelli,
2005; Lobo, 2009). The remaining cells in the striatum are interneurons of the
cholinergic or GABAergic type, which may be modulated by DA and other
neurotransmitters (Gittis, et al., 2010; Partridge, et al., 2002; Tozzi, et al., 2011; Vincent,
et al., 1983).

Aging and Dopamine-Neuron Dysfunction: Parkinson's Disease and
Parkinsonism
Age is the most substantial risk factor for developing PD of the nonfamilial/idiopathic type (Bennett, et al., 1996; Collier, et al., 2011; Fearnley and Lees,
1991), which is typically diagnosed upon emergence of clinical symptoms in the 6th
decade of life or beyond (Khealani and Baig, 2006). Although early-onset forms of PD
exist, which are associated with specific genes (Dawson and Dawson, 2003; Schiesling,
et al., 2008; Vila and Przedborski, 2004), they represent a small proportion of total PD
cases (~5%) (Cookson, et al., 2005; Dauer and Przedborski, 2003; Davie, 2008).
Genetic studies of early-onset PD have helped to link several genes to the more
common, aptly-named, idiopathic type (Cookson, et al., 2005; Illarioshkin, et al., 2007;
Sharma, et al., 2011), which has a poorly understood pathoetiology. Some of the
contributing factors to the development of idiopathic PD will be discussed. For the
purposes of this work, the remaining discussion will be directed at the idiopathic
(sporadic) type.
The role of DA in the basal ganglia has been studied extensively and implicated
in movement disorders, particularly regarding loss of DA neurons in the SN (Adams and
Victor, 1977; Bennett, et al., 1996; Fearnley and Lees, 1991; Hoehn and Yahr, 1967;
Hornykiewicz and Kish, 1987). Parkinson’s disease involves the progressive and
selective loss of midbrain DA neurons in the SN with a consequent loss of DAergic input
to the striatum (Bernheimer, et al., 1973; Fearnley and Lees, 1991; McGeer, et al.,
1988). Clinically, PD is characterized by cardinal motor symptoms (bradykinesia, rigidity,
postural instability and tremor (Hoehn and Yahr, 1967)) caused, in part, by increased
activity in the indirect pathway and decreased activity in the direct pathway, which
contribute to reduced thalamic output to the motor cortices (Mink, 2007). Of note, a
definitive diagnosis of PD can only be made post mortem to confirm defining
pathological features: gross depigmentation patterns of DA neurons and cytoplasmic
inclusion (Lewy) bodies (Foltynie, et al., 2002; Jellinger, 1999).
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Although other DA neurons and neurotransmitter systems are dysfunctional in
PD (Barone, 2010; Braak, et al., 2003a; Huot, et al., 2011), perhaps the most striking
pathological feature is the characteristic degeneration of DA neurons in the SN. The
relative selectivity of degeneration in the SNc proper (Fearnley and Lees, 1991; Uhl, et
al., 1985) has prompted more intense examination of properties of these neurons for
insights into PD etiology. Prevailing theories on cell death in PD include: oxidative
damage (Hald and Lotharius, 2005; Jenner and Olanow, 1996), mitochondrial
dysfunction (Abou-Sleiman, et al., 2006) and abnormal protein aggregation (Golbe,
2003) related to α-synuclein (the main constituent of Lewy bodies) (Spillantini, et al.,
1997). These proposed processes are conceivably not mutually exclusive and interact
with multiple genetic and environmental factors (Braak, et al., 2003b; Choi, et al., 2006;
Chung, et al., 2001; Greenamyre and Hastings, 2004). It is proposed that an intrinsic
property of DA neurons, containing DA, leads to oxidative damage due to the autooxidation of cytosolic DA to the reactive quinone (Greenamyre and Hastings, 2004;
Sulzer and Zecca, 2000). Quinone formation may lead to increased generation of
reactive oxygen species that deleteriously affect mitochondrial function. Mitochondrial
dysfunction may cause additional oxidative stress, cellular damage/death (Berman and
Hastings, 1999; Jana, et al., 2011) and abnormal protein interactions that contribute to αsynuclein-associated neurotoxicity (Lewy-body deposition) (Conway, et al., 2001).
Nigrostriatal DA neurons generate action potentials in “pacemaker”-like continuous
patterns that have been suggested to cause increased energetic demands leading to
mitochondrial stress (Surmeier, 2007) – another potential source of reactive oxygen
species generation and oxidative stress that contribute to Lewy-body formation and
neurodegeneration (Greenamyre and Hastings, 2004). Additionally, the DAT has been
suggested to predispose nigrostriatal DA neurons to injury because of a relatively high
density of DAT expression (Cass and Gerhardt, 1995; Shimada, et al., 1992; Storch, et
al., 2004). Thus, increased cytosolic DA transported from the extracellular space by the
DAT may auto-oxidize – forming reactive quinones (Sulzer and Zecca, 2000). The DAT
also plays a critical role in facilitating cellular entry of toxins (1-methyl-4-phenyl-1,2,3,6tetrahydropyridine (MPTP) (Gainetdinov, et al., 1997) or 6-hydroxydopamine (6-OHDA))
used to experimentally induce DA-neuron death (Storch, et al., 2004). Thus, the DAT
may increase susceptibility of DA neurons to existing or unknown environmental toxins
(Cicchetti, et al., 2009; Opeskin and Anderson, 1997).
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Relationships between PD and aging are muddled because of the observed
motor

impairment

commonly

associated

with

aging

termed

“age-associated

parkinsonism”, a condition that can be difficult to differentiate from sub-clinical PD
(Bennett, et al., 1996). Parkinsonism is also used in the literature to refer to sub-types of
movement disorders (including primary PD) as well as experimental models of PD
(Baldereschi, et al., 2000; Christine and Aminoff, 2004; Kitayama, et al., 1992; Opeskin
and Anderson, 1997; Samaranch, et al., 2010). Although PD is considered a disease of
aging, the specific pattern of neurodegeneration seen in subdivisions of the SNc
contrasts the loss seen in the aged (non-PD) brain (Fearnley and Lees, 1991; Kish, et
al., 1992). The pattern distinctions suggest that PD should not be considered an
accelerated-aging disease of DA neurons (Fearnley and Lees, 1991). The striking loss of
functional DA neurons at the onset of PD (~60%)(Bernheimer, et al., 1973) also
contrasts the neurodegeneration seen in aging (7-33%)(Fearnley and Lees, 1991; Hirai,
1968; McGeer, et al., 1977), suggesting that more understated changes in neuron
function produce age-associated parkinsonism. There is substantial variability in the
reported degree of degeneration in aging because of differences in defined anatomical
boundaries, inclusion/exclusion of individuals with existing neurodegenerative disease or
sub-clinical PD as well as stereological methods (Stark and Pakkenberg, 2004). Some
studies suggest very little neurodegeneration accompanies normal aging (Kubis, et al.,
2000). It is proposed that changes in more dynamic properties of DA-release and uptake lead to age-associated parkinsonism in animal models (Gerhardt, et al., 1995;
Hebert and Gerhardt, 1998; Hebert and Gerhardt, 1999; Yurek, et al., 1998) and humans
(Volkow, et al., 1998a; Volkow, et al., 1994).
In the case of primary PD, current medical management involves a combination
of drug therapies that typically act by modulating DA -synthesis, -metabolism and/or receptor activation (Djaldetti and Melamed, 2002; Fahn, et al., 2004; Goudreau, 2006;
Salawu, et al., 2010; Yamada and Yasuhara, 2004). When pharmacological therapies
are not effective, surgical therapies may re-establish balance through selective lesioning
or stimulation of non-DAergic nuclei within the basal ganglia (Okun and Vitek, 2004).
Current medical and surgical management approaches are only symptomatic treatment
strategies and do not slow disease progression. The treatment of underlying
neurodegeneration to slow disease progression is one of the great prospects of
neurotrophic factor use in PD (Chiocco, et al., 2007; Dauer, 2007; Peterson and Nutt,
2008).
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Trophic Factors
In the most general and basic terms, trophic factors are described as naturally
occurring proteins with survival- and function -enhancing effects. The term “neurotrophic
factor” has been used interchangeably with trophic factor when biological effects are
concerning nerve cells (Levi-Montalcini, 1987; Peterson and Nutt, 2008). The first trophic
factor shown to affect nerve cells was identified in the 1950s, nerve growth factor (NGF)
(Cohen, et al., 1954). Since the discovery of the first neurotrophic factor, additional
neurotrophic factors, families and sub-families have been identified that are relevant to
the treatment of PD and other neurodegenerative diseases (Chiocco, et al., 2007;
Dauer, 2007; Peterson and Nutt, 2008).
Glial Cell line-Derived Neurotrophic Factor: A Potent Trophic Factor for
Midbrain Dopamine Neurons
Trophic factors have shown promising results in the treatment of PD (Peterson
and Nutt, 2008). Perhaps the most promising and well-characterized neurotrophic factor
concerning DA neurons is glial cell line-derived neurotrophic factor (GDNF), a distant
member of the transforming growth factor-β (TGF-β) superfamily (Lin, et al., 1993;
Saarma, 2000). Positive behavioral, histological and neurochemical effects have been
demonstrated in the aged rodent (Hebert and Gerhardt, 1997) and non-human primate
(Ai, et al., 2003; Grondin, et al., 2003; Maswood, et al., 2002) following GDNF treatment.
Although the enhancing effects on DA neurons by GDNF is applicable to aging and
parkinsonism, the majority of the discussion following will focus on GDNF studies in
primary PD.
Following numerous studies showing modulation of DA systems by GDNF
(Georgievska, et al., 2002; Grondin, et al., 2003; Grondin, et al., 2002; Hebert and
Gerhardt, 1997; Hebert, et al., 1996; Lindvall and Wahlberg, 2008; Rosenblad, et al.,
1996), GDNF progressed to clinical trials. Because of the large size and other
biochemical characteristics of neurotrophic factors, blood brain barrier permeability is
unlikely (Pardridge, 2003) and intracerebral catheter administration is a necessary route
to reach target brain areas and maintain protein integrity (Thorne and Frey, 2001).
Based on non-human primate studies demonstrating significant behavioral improvement
after GDNF delivery to the ventricles (Gash, et al., 1996; Zhang, et al., 1997), GDNF
was delivered to the ventricles in a double-blind clinical trial. Trials using ventricular
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delivery produced adverse side effects and failed to show significant clinical benefit – a
finding attributed to inadequate penetrance to target brain areas (Kordower, et al., 1999;
Nutt, et al., 2003). Although small open-label trials using direct delivery to the putamen
improved motor scores measured by the Unified Parkinson’s Disease Rating Scale
(UPDRS) (Gill, et al., 2003; Slevin, et al., 2005), a larger placebo-controlled trial did not
meet proposed endpoints (25% improvement)(Lang, et al., 2005). Initial results were
promising, however, placebo-controlled trials were halted due to safety concerns: the
presence of neutralizing antibodies in some patients (Tatarewicz, et al., 2007) and
indications of cerebellar toxicity in non-human primate studies (Hovland, et al., 2007) – a
finding not reproduced in patients (Chebrolu, et al., 2006)). The trials are viewed as
highly controversial with numerous conclusions and mixed opinions. There are
reservations about the design of the placebo-controlled study and interpretation of safety
issues (Hutchinson, et al., 2007; Matcham, et al., 2007; Penn, et al., 2006). Also, lack of
consistency in several important variables (e.g. catheter type/infusion method and dose)
makes interpretation problematic (Sherer, et al., 2006).
Following the GDNF clinical trials, it has been suggested that limited diffusion to
the preferred brain regions underlies some of the shortcomings (Salvatore, et al., 2006)
(Salvatore, et al., 2003). Although neurotrophic factors are promising candidates for the
treatment of neurodegenerative disease, the considerations for delivery to the CNS are
daunting, if not limiting (Peterson and Nutt, 2008; Thorne and Frey, 2001). The delivery
obstacles associated with trophic factor delivery to the brain have prompted the search
for smaller mimetic molecules with trophic or trophic-like effects and greater potential for
modification to improve bioavailability (Bespalov and Saarma, 2007).

Small Peptides as Trophic-like Molecules
The inherent bioavailability limitations of large trophic molecules (e.g large size
and heparin-binding characteristics)(Salvatore, et al., 2006) stimulated interest in smaller
biologically-active molecules that may provide comparable therapeutic benefit and avoid
some specific delivery issues (Beglova, et al., 2000; Bespalov and Saarma, 2007;
Maliartchouk, et al., 2000; Peleshok and Saragovi, 2006; Saragovi and Gehring, 2000).
In the case of GDNF, these small molecules may come in the form of propeptides – peptides derived from the pro-sequence (Bradley, et al., 2010; Immonen, et
al., 2008; Kelps, et al., 2011). GDNF and other trophic molecules are processed as
immature precursors that are be cleaved to yield the mature trophic molecule and pro11

protein(s) (Chao and Bothwell, 2002; Lee, et al., 2001). The role of the pro-protein(s)
was thought to be limited to regulation of folding and secretion of the mature secreted
protein (Gray and Mason, 1990). Recently, distinct signaling actions of uncleaved trophic
factors (pro-neurotrophins) have been identified for brain-derived neurotrophic factor
(BDNF) (pro-BDNF) and NGF (pro-NGF) (Ibanez, 2002; Nykjaer, et al., 2004; Teng, et
al., 2005) that are unique from the signaling actions of the mature trophic factor alone.
There is also increasing evidence for conservation of pro-protein sequences among
related species (Bradley, et al., 2010; Lee, et al., 2001). Taken together, these findings
suggest novel roles and possible physiological actions of pro-peptides that may act as
more than just chaperones (Bradley, et al., 2010). The comparatively small size and less
complex structure of pro-protein peptides increases their clinical utility because they may
be more easily modified and are typically stable – making delivery and peptide
manipulation to increase bioavailability more feasible for clinical applications (Thorne
and Frey, 2001).
Of particular interest, two synthetic peptides (of 5- and 11- amino acids) are
predicted to be generated from the proteolytic processing of the pro-sequence of proGDNF. The human and rodent forms of these pro-peptides have been investigated by
our group and others (Bradley, et al., 2010; Immonen, et al., 2008; Kelps, et al., 2011).
Notably, the peptides have been investigated for their effect on DA neurons in vitro and
in vivo. Recent studies show evidence for considerable biological activity relevant to DAneuron dysfunction in PD/parkinsonism (Bradley, et al., 2010; Kelps, et al., 2011). The
smaller size makes these pro-peptides excellent candidates for modification to
administer by oral or intranasal routes (Born, et al., 2002). Nasal or oral administration is
a favorable alternative to intracranial delivery or gene therapy approaches, which are
required for GDNF delivery (Bjorklund, et al., 2000; Gill, et al., 2003; Grondin, et al.,
2002; Patel and Gill, 2007).
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Chapter One: Figures

Figure 1.1 Schematic of a Dopamine Synapse
Several aspects of DA neurotransmission are depicted in this simplified and generalized
dopamine (DA) synapse b. Dopamine is synthesized in the presynaptic neuron by the
conversion of tyrosine to levodopa (L-DOPA) by tyrosine hydroxylase (TH), the ratelimiting enzyme in DA synthesis. Dopamine is produced by the actions of aromic aminoacid decarboxylase (AAADC) on L-DOPA. Intracellular DA may be vesicularized via the
vesicular monoamine transporter (V-MAT) in the presynaptic neuron and released in a
Ca++-dependent mechanism upon membrane depolarization sufficient to reach an action
potential. Cytosolic DA (non-vesicularized) may be metabolized by an intracellular
enzyme, monoamine oxidase (MAO-a), localized to the outer membrane of the
mitochondria. Dopamine released to the extracellular space is metabolized by MAO-b
and/or catechol-o-methyltransferase (COMT) to generate metabolic products: 3,4-
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dihydroxyphenylacetic acid (DOPAC), homovanillic acid (HVA) and a less prevalent
intermediate in the CNS 3-methoxytyramine (3-MT). Extracellular DA is removed from
the extracellular space by the Na+-Cl--dependent DA transporter (DAT). Extracellular DA
may bind to DA receptors, which are broadly classified into D1- and D2-subtypes based
on stimulatory or inhibitory effects on adenylate cyclase (AC). Both subtypes are present
on the postsynaptic neuron. Dopamine receptors present on the presynaptic neuron,
autoreceptors (D2), are also targets for DA action and may modulate DA -release and synthesis. Figure modified from Cooper et al., 2003.
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Figure 1.2 Schematic of Basal Ganglia
A simplified schematic diagram of components and connections of the basal ganglia is
shown. Dopamine innervation of the striatum arises from midbrain DA-neuron cell bodies
in the SNc - the nigrostriatal projection. Activity within the basal ganglia is discussed
using distinctions between the direct and indirect pathway, where DA innervation
increases and decreases activity in each pathway, respectively. Specifically, activation of
D1 receptors (direct pathway) leads to activation of inhibitory (GABA) fibers projecting
from the striatum to the GPi and SNr. Inhibitory projections from the GPi and SNr project
to the thalamus. The action of DA innervation of the striatum causes inhibitory
projections to the thalamus to be inactivated (disinhibition). Thus, excitatory projections
from the thalamus to the motor cortices are active. In the indirect pathway, DA activation
of D2 receptors in the striatum decreases activity of inhibitory projections from the
striatum to the GPe. Projections from the GPe inhibit GABAergic projections from the
GPi/SNr to the thalamus – allowing excitatory thalamic output to the motor cortices. The
GPi/SNr may also be activated by excitatory glutamate projections from the STN, which
are also under inhibitory control of the GABAergic projections from the GPe through the
indirect pathway. Thus, decreased activity in the indirect pathway results from DA
stimulation of D2 receptors – effectively increasing thalamic output to the motor cortices.
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Abberviations used: substantia nigra pars compacta (SNc), globus pallidus [GP, internal
segment (GPi), external segment (GPe)], substantia nigra pars compacta (SNc),
substantia nigra pars reticulata (SNr), subthalamic nucleus (STN), γ-aminobutyric acid
(GABA). Figure modified from Kandel et al., 2000.
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Thesis Outline
In these studies the effect of trophic factors and trophic-like molecules were
investigated in the context of nigrostriatal DA-neuron function and movement disorders –
topics highly concerned with PD and age-associated parkinsonism. In Chapter Three,
the effects of synthetic phenotypic-mimetic trophic peptides – DNSPs – were
investigated with attention to evoked DA release and tissue neurochemical content after
a single peptide treatment to the SN. In particular, an 11-amino-acid amidated peptide
derived from the pro-region of glial cell line-derived neurotrophic factor (GDNF) was
investigated. After several experiments that have shown enhanced DA-neuron function
associated with this peptide, the peptide has been named Dopamine-Neuron Stimulating
Peptide-11 (DNSP-11). These studies were designed to test the overarching hypothesis:
DNSP-11 enhances dynamic properties of DA-neuron function in the nigrostriatal
pathway. Specifically, sub-regional effects of DNSP-11 on DA release in the striatum
were investigated along with the time course of effects – investigating DA release 1-, 2and 4-weeks after a single treatment to the SN. The most exciting finding of these
studies is the enhanced striatal DA release after treatment with DNSP-11, a finding that
suggests enhanced function of DA neurons in the SN. Co-injection of DNSP-11 and a
related peptide, Dopamine-Neuron Stimulating Peptide-5 (DNSP-5), was investigated to
determine if the related pro-peptides exhibited synergistic effects on DA neurochemical
function. Interestingly, the enhancing effects on extracellular neurochemical levels, as
seen previously with DNSP-11 treatment alone, were not reproduced. Whole tissue
dopamine neurochemistry, however, was enhanced after treatment with the peptide
mixture – a finding not seen with DNSP-11 treatment alone. Although the functional
relationship between related peptides derived from the GDNF pro-sequence is unclear,
we believe DNSP-11 and possibly other synthetic peptides are promising therapeutic
candidates for DA-neuron -degeneration and -dysfunction (e.g. Parkinson’s disease).
In Chapter Four, dynamic properties of DA-neuron function were characterized in
a unique transgenic mouse model with a partial GDNF depletion – having a single
functional GDNF allele (Gdnf+/-). Middle aged, 12-month-old, Gdnf+/- mice have
demonstrated diminished spontaneous locomotor activity and enhanced synaptosomal
DA uptake compared to wildtype (WT) mice. In these studies, the following hypothesis
was tested: GDNF depletion causes in vivo alterations in DA-neuron function that
contribute to locomotor function. In the presented studies, specific functional indices of
DA-neuron function – DA-uptake and -release – were investigated in vivo. The major
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finding of these studies is that DA uptake by the DAT appears to contribute to motor
deficits demonstrated in the Gdnf+/-. Other considerations that may influence the
behavioral phenotype of Gdnf+/- mice were investigated: DA-receptor expression and DA-synthesis and -metabolism. A slight decrease in tissue levels of DA was indicated as
well as upregulation of mRNA and protein levels of the DA D2-receptor. Altogether, these
studies characterize a unique mouse model of neuron dysfunction caused by a GDNF
protein reduction. The findings indicate an important role of GDNF in aging and
nigrostriatal dysfunction.
In Chapter Five, the use of GDNF supplementation in age-related changes in
DA-neuron function was investigated in Gdnf+/- mice. The hypothesis that DA-neuron
deficiencies and related behavioral impairments are reduced by GDNF treatment was
tested. To determine if age-related DA-neuron abnormalities were reversible, GDNF was
administered to the striatum of 12-month-old Gdnf+/- mice and similar indices of DAneuron function were investigated as outlined in Chapter Four. These studies further
investigated the consequences of trophic factor depletion and examined the function of
trophic factor treatment to ameliorate abnormalities in nigrostriatal DA-neuron function.
Notably, markers for functional DA neurons and locomotor activity were increased in
Gdnf+/- mice and were comparable to WT counterparts.

Copyright © Ofelia Meagan Littrell 2011
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Chapter Two: Materials and Methods

Reagents
Most reagents were purchased from Sigma-Aldrich (St. Louis, MI). Exceptions
are noted.

Animals and Procedures
Ethics Statement
Protocols for animal care were in agreement with NIH approved guidelines and
compliant with local institutional protocols at the University of Kentucky Medical Center
(rats) and the Medical University of South Carolina (mice). Procedures were in strict
agreement with the Guide for the Care and Use of Laboratory Animals. Surgical
procedures followed AALACI guidelines and were approved by the Institutional Animal
Care and Use Committee.

Animal Housing and Husbandry
Animals were maintained under a 12:12 hour light:dark cycle with food and water
available ad libitum at an ambient temperature of 20-22° C. Procedures and experiments
were performed during the light cycle.

Rat Studies
Fischer 344 (F344) rats were obtained from Harlan Laboratories Inc.
(Indianapolis, IN). All rats were 3-6 months of age. Rats were housed 1 per cage in the
University of Kentucky animal facilities.
Mouse Studies
A nonfunctional GDNF allele was generated by replacing part of the GDNF
protein encoding exon, exon 3, with a selectable marker neomycin phosphotransferaseexpressing cassette. Generation and genotyping of Gdnf+/- mice is described in detail in
previous work (Pichel, et al., 1996). Transgenic mice and non-transgenic littermate
control mice were obtained from a colony established at the Medical University of South
Carolina. Mice were bred on a C57Bl/6J background in agreement with NIH-approved
protocols. After transfer to the University of Kentucky, mice were acclimated for a
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minimum of 1 week before use in experiments or surgical procedures. Mice were housed
3-4 per cage. Male Gdnf+/- mice (12-months-old) were compared with age-matched WT
littermates in all experiments. Age-matched C57/BL6 mice (non-littermate/nontransgenic) (Charles River Laboratories, Wilmington, MA) were used as an additional
control group in some experiments (see Chapter Five: GDNF Replacement in Gdnf+/Transgenic Mice).
Intracranial Drug Delivery - Survival Surgical Procedures
Instruments used for survival procedures were sterilized and aseptic techniques
were followed using a laminar flow hood to maintain aseptic working conditions. Large
fixed equipment and instruments that were not autoclave-compatible were disinfected
with 70% ethanol and/or covered with a sterile drape. Animals used for survival surgical
procedures were anesthetized with isoflurane gas (1.5-2.5% in O2) and positioned in a
stereotaxic frame for the rat or mouse (Kopf Instruments, Tujunga, CA, USA). A
craniotomy was performed for access to the targeted structures and drugs were
delivered using a 26-gauge needle (cannula only) (22026-01, point style-3; Hamilton
Company, Reno, NV) attached to a 25-μL Hamilton syringe (80408, point style 3;
Hamilton Company, Reno, NV) using plastic tubing (Zeus Inc., Orangeburg, SC). The
syringe needle was slowly lowered into the brain to the appropriate stereotaxic
coordinates (see specific chapters) using a microdrive apparatus (MO-10; Narishige
International, East Meadow, NY). Solution delivery began 5 minutes after lowering to the
appropriate depth. Solution delivery was controlled using a 25-μL Hamilton syringe
mounted on a KD Scientific model infusion pump (model 100, KD Scientific Inc.,
Holliston, MA). The needle remained in the brain after completing solution delivery and
was slowly retracted after 10 minutes. The overlying burr hole was covered with bone
wax and the incision was closed using dissolvable sutures (4-0 Caprosyn™; Covidien;
Norwalk, CT). Oral analgesic (RIMADYL® (carprofen), 2 mg p.o.; Bio-Serv; Frenchtown,
NJ) was provided following surgical procedures in rats. Topical analgesic ointment
(Neosporin® with pramoxine HCl; Rite Aid Corp.) was applied to the incision site in mice
following surgical procedures. During surgical procedures and the immediate recovery
period following surgery, animals were rested on a heating pad connected to a recirculating water bath (Gaymar Industries, Inc., Orchard Park, NY) maintained at 37°C.
Animals recovered in their home cage under observation in the laboratory (~2 hours)
before transport to the animal housing facility. Animal health was assessed daily for a
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minimum of 1 week for signs of postoperative distress. Particular treatment
considerations are explained in greater detail in the subsequent chapters.
In Vivo Electrochemical Recording and Microdialysis – Non-Survival
Surgical Procedures
Animals were anesthetized with urethane (1.25 g/kg, 0.9% NaCl i.p.), positioned
in a stereotaxic frame designed for the rat or mouse (Kopf Instruments, Tujunga, CA,
USA) and rested on a heating pad connected to a re-circulating water bath (Gaymar
Industries, Inc., Orchard Park, NY) maintained at 37°C. For electrochemical recordings,
a craniotomy was performed for access to the striatum and the overlying dura was
reflected prior to insertion of the carbon fiber microelectrode/micropipette assembly (see
Electrode

Construction

and

Preparation

and

Micropipette

Preparation).

The

microelectrode assembly was stereotaxically placed in contact with the brain and
lowered to the targeted recording depth(s) using a microdrive apparatus (MO-10;
Narishige International, East Meadow, NY). For electrochemical recordings, a burr hole
was created (distant from the recording sites) to allow placement of a miniature Ag/AgCl
reference electrode (see Preparation of Miniature Reference Electrode) in contact with
the brain (Hascup, et al., 2007).
Microdialysis probes were stereotaxically placed in contact with dura and slowly
lowered to the desired depth using the vertical arm of the stereotaxic frame.
In vivo Electrochemistry

Principles of Amperometry
By applying a potential to an electrode, the resulting change in current generated
by redox reactions involving electroactive species is measured at the electrode surface.
Applied potential is maintained by a potentiostat, which maintains a constant potential
difference between the recording (working) electrode and the reference electrode halfcell. Current generated from the oxidation and reduction of electroactive molecules is
faradaic and linearly correlated with the concentration of electroactive molecules, which
donate or accept electrons in established stoichiometric ratios. Although several
variations of amperometric measures exist, generally, these techniques provide sensitive
measurements and allow for rapid sampling rates (seconds) to monitor neurochemical
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events near real-time. For a more detailed review and discussion of electrochemical
methods see (Adams, 1990; Cahill, et al., 1996; Gerhardt, et al., 2000).
In our recordings, the Fast Analytical Sensing Technology-16 mark II system
(FAST-16 mk II; Quanteon LLC, Nicholasville, KY) was used to amplify, integrate and
digitize current measured using carbon fiber microelectrodes (see Electrode
Construction and Preparation) and chronoamperometry (see Chronoamperometry).
Chronoamperometry
A square-wave pulse (200 millisecond (msec) duration, 0.0 V (100 msec) to
+0.55 V (100 msec)) (Figure 2.1) was applied to the carbon fiber microelectrode versus
a Ag/AgCl reference electrode and repeated at 1 Hz (FAST-16 mk II system; Quanteon
LLC, Nicholasville, KY). The analyte of interest (DA in this example) was oxidized at
+0.55 V, producing an increase in current detected by the electrode. The oxidation
product (dopamine-ο-quinone) was reduced when the potential was stepped back to 0.0
V, also producing a change in current measured at the electrode surface (Figure 2.1).
The reduction:oxidation ratio (Figure 2.2) is a distinguishing feature for some
electroactive species in the brain and is used to confirm chemical identity (Gerhardt and
Hoffman, 2001). Oxidation and reduction currents were digitized during the last 80 ms of
each pulse using the FAST-16 mkII recording system (Quanteon, LLC, Nicholasville,
Kentucky) as outlined in previous work from our laboratory (Gerhardt, et al., 1986;
Hebert, et al., 1996).
Electrode Construction and Preparation
Carbon fiber microelectrodes were manufactured using minor modifications from
previously established methods (Gerhardt and Hoffman, 2001). Briefly, single carbon
monofilament

(30-33

μm

diameter

“fibers”)(Specialty

Materials

Inc.,

Lowell,

Massachusetts) was threaded into a pulled (Kopf Instruments, Tujunga, CA) glass
capillary (Sodalime; 4 mm O.D., 0.7 mm wall thickness (before pulling); Glass
Warehouse, Millville, NJ) and secured using Epoxylite® (#6001; Electrical Insulation
Suppliers (EIS), Atlanta, GA). The capillary tube was filled with graphite-epoxy resin (PX
grade; Dylon Industries Inc., Cleveland, OH), excess glass was trimmed and a 30-gauge
enamel-coated copper wire (#278-1345; Radio Shack) was inserted into the graphiteepoxy and secured with Epoxylite®. The pulled end of the glass capillary was bumped
and the exposed carbon-fiber tip was trimmed to a length of ~150 μm.
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The sensitivity and selectivity for DA versus other endogenous electroactive
molecules were enhanced by coating the electrode tips with Nafion® (5% solution,
Aldrich Chemical Co., Milwaukee, WI) (Gerhardt and Hoffman, 2001). Nafion® is a
perfluorosulfonated Teflon® derivative that is permeable to cationic species but not
anionic species. Thus, potential interfering currents generated by the oxidation/reduction
of acidic electroactive compounds in the brain were minimized (Gerhardt, et al., 1984).
Carbon fiber electrodes were baked at 200°C for 5 minutes and then slowly swirled (~4
times, 4 seconds total) in Nafion® solution. Electrodes were baked again for 5 minutes
at 200°C. For connection to the FAST-16 mark II headstage/potentiostat (Quanteon,
LLC, Nicholasville, KY), a gold pin amphenol (Mill-Max Mfg. Corp., Oyster Bay, NY; Part
no: 3603-0-07-21-00-00-08-0) was soldered to the copper wire end of each carbon fiber
electrode.
Electrode Calibration
Nafion®-coated carbon fiber electrodes were calibrated prior to use in vivo.
Phosphate buffered saline (PBS) solution (0.05 M, pH = 7.4) was gently stirred using a
battery-operated, portable magnetic stir plate (Barnant Co., Model #700-0153). The
glass Ag/AgCl reference electrode (Bioanalytical Systems, West Lafayette, IN; Model
#RE-5B) and recording tip of the Nafion®-coated carbon fiber microelectrode were
submerged

in

the

buffer

solution.

High-speed

in

vivo

chronoamperometric

measurements were carried out as previously described (Chronoamperometry).
Parameters quantified included: linearity of response to DA, selectivity and limit of
detection (LOD) for DA (Figure 2.3). Microelectrodes showed linear responses to serial
additions of DA (2 – 6 μM, effective beaker concentrations). Additions of ascorbate (250
μM, Fisher Scientific) were used to determine the selectivity of the recordings for DA.
Changes in DA concentration in vivo were expressed as change from a stable baseline
using the calibration curve for each particular microelectrode. Specific calibration values
are described in the methods sections of the subsequent chapters.
Preparation of Miniature Reference Electrode
A miniature Ag/AgCl reference electrode (A-M Systems, Inc., Catalog #786500;
0.008 inch bare, 0.011 inch coated) was used for in vivo electrochemical recordings.
Reference electrodes were prepared by stripping the Teflon® coating from the tip (~1
cm) of each end of the silver wire. One end was soldered to a gold pin amphenol (Mill23

Max Mfg. Corp., Part #3603). The other end was submerged in a 1M HCl solution that
was saturated with NaCl. Using a 9-volt power supply (Elenco Precision, Model XP-620),
the reference electrode was anodized while submerged in the plating bath solution. A
platinum wire connected to the negative lead (the cathode) was also placed in the
plating solution. The potential was applied for approximately 10 minutes and reference
electrodes were stored in 3M NaCl for at least 1 hour prior to use in vivo.
Micropipette Preparation
For pharmacological manipulation in vivo, a glass micropipette (A-M Systems,
Inc., Everett, WA; 1 mm o.d., 0.58 i.d.,) was pulled using a vertical pipette puller (Kopf
Instruments, Tujunga, CA) and bumped to an inner tip diameter of 7-15 μm. The
micropipette was then affixed flush with the Nafion®-coated microelectrode (Figure 2.1)
at a distance of ~200 μm using sticky wax (Kerr Corp., Orange, CA, USA).

Local Application of Solutions In Vivo
Physiological solutions were filtered (0.22 μm) and pH adjusted (7.2-7.4) before
filling the micropipette for in vivo application. After stereotaxic placement of the
microelectrode/“filled”-micropipette assembly into the brain, baseline recordings were
carried out for a minimum of 1 hour. When a stable baseline was reached, the recording
assembly was lowered to the targeted recording depth. Local application of solutions
was accomplished by pressure ejection of nitrogen gas (Palmer, et al., 1980). A
picosprizter III (Parker-Hannifin, NJ) was used to control the amount of solution applied
by manipulating the pressure (10-30 psi) or duration (0.5-2.5 seconds). In order to
determine the amount of solution ejected, the solution volume (displacement) was
monitored using a stereomicroscope fitted with a reticule (Friedemann and Gerhardt,
1992). The purpose and constituents of solutions used are addressed in the subsequent
chapters.
Tissue Preparation and Neurochemical Analysis of Tissues (HPLC-EC)
All tissue samples to be analyzed for neurochemical content were placed into
pre-weighed microcentrifuge tubes, weighed and placed on dry ice. After dissections,
tubes containing tissues were stored at -80°C until analysis by high-performance liquid
chromatography with electrochemical detection (HPLC-EC). Technical details about
dissection methods are explained in the subsequent chapters.
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In preparation for HPLC-EC analysis, samples were sonicated in cold mobile
phase (pH = 4.05-4.15) with dihydroxybenzylamine (DHBA) as an internal standard.
Samples were centrifuged at 16,000 × g for 10 minutes (-4 °C). The filtered supernatants
were injected (50 μL) into the HPLC system equipped with dual-coulometric
electrochemical detectors (Hall, et al., 1989) (also see Neurochemical Determination by
HPLC-EC). The system detection limits were < 1 ng/g tissue wet weight for the analytes
of interest. Dopamine and metabolites of DA (DOPAC and HVA) were identified by peak
retention time (determined from standards) and were quantified by peak area using
standard concentrations of analytes. Neurochemical content was expressed as ng/g wet
weight of tissue. Neurochemical analyses of tissues using HPLC-EC were performed by
Stewart Surgener (Chapter 4) and Wayne Cass, Ph.D. (Chapter 3, Chapter 5).

Portions of these methods have been previously published in the manuscript:
Littrell, O.M., Pomerleau, F., Huettl, P., Surgener, S., McGinty, J.F., Middaugh, L.D.,
Granholm, A.C., Gerhardt, G.A., Boger, H.A. 2010. Enhanced dopamine
transporter activity in middle-aged Gdnf heterozygous mice. Neurobiol
Aging.doi:S0197-4580(10)00446-X[pii] 10.1016/j.neurobiolaging.2010.10.013.
Permission was obtained from publisher for use in this dissertation.
Copyright © Ofelia Meagan Littrell 2011
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Chapter Two: Figures

Figure 2.1 Chronoamperometry with Carbon-Fiber Microelectrodes:
Recording
Assembly used for Electrochemical Detection of Dopamine
Inset: A square wave potential is applied to the working electrode versus a Ag/AgCl
reference electrode. Square wave potentials (+0.55 V (100 ms) and 0.0 V (100 ms))
were repeated at 1 Hz (inset). The resulting oxidation and reduction currents were
digitally integrated during the last 80 ms of each pulse and averaged to a 1 Hz sampling
rate. In addition to high temporal resolution (seconds), electrochemical techniques using
microelectrodes provide a high degree of spatial resolution (microns) because only
molecules that come in contact with the recording electrode surface are detected. A
micropipette can be affixed flush with the microelectrode in order to locally apply
solutions.
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Figure 2.2 Chronoamperometric Measures for the Detection of Dopamine
Local application of DA in the brain (arrow) results in a transient change in current
measured by the electrode (inset: axes units). Dopamine signals may be differentiated
from other electroactive species based on the ratio of reduction:oxidation currents
(Gerhardt and Hoffman, 2001).
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Selectivity and Sensitivity for Dopamine
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Figure 2.3 In vitro Carbon Fiber Microelectrode Calibration
A) Oxidation current is shown for a carbon fiber microelectrode calibrated in vitro for
selectivity and sensitivity for DA (inset: axes units). Nafion®-coated microelectrodes are
challenged with an addition of ascorbate (AA), an electroactive molecule present in high
concentration in the brain. Three serial additions of DA demonstrate a comparatively
robust increase in current that is linear (R2 > 0.99) with respect to concentration. Inset:
(a) The change in oxidation current is used to calculate the sensitivity (slope, nA/μM) of
individual electrodes in order to correlate oxidation current change with a DAconcentration value. The limit of detection (LOD, μM) is calculated by dividing the
standard deviation of the baseline oxidation current (nA) by the slope (nA/μM) using a
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signal:noise ratio of 3. B) Reduction and oxidation currents following sequential additions
of DA are shown (inset: axes units).
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Chapter Three: Characterization of the Neurochemical Effects of DNSP-11

Introduction
Parkinson’s disease is characterized by the loss of DA neurons in the SN and a
concomitant decrease in synaptic DA in the striatum (Bernheimer, et al., 1973). Current
therapies may improve motor deficits associated with nigrostriatal dysfunction by
enhancing DA-synthesis and/or decreasing -metabolism (Goudreau, 2006; Salawu, et
al., 2010). Unfortunately current therapies are only symptomatic treatment regimens,
which fail to slow the disease progression and often cause unfavorable side effects
(Muller and Russ, 2006; Salawu, et al., 2010). One promising PD therapeutic agent,
GDNF, has shown robust restorative and protective effects on DA neurons (Grondin and
Gash, 1998; Hebert and Gerhardt, 1997; Kearns, et al., 1997; Lin, et al., 1993). Despite
evidence for therapeutic potential from phase I clinical trials (Gill, et al., 2003; Slevin, et
al., 2005), the clinical utility of GDNF has been questioned because of evidence for
toxicity (Lang, et al., 2005), limited diffusion to target areas (Salvatore, et al., 2006;
Sherer, et al., 2006) and phase II trials that did not reach proposed endpoints.
Considering the potential of neurotrophic factors as therapeutics in neurodegenerative
disease (Peterson and Nutt, 2008) and particular delivery issues related to binding
characteristics of GDNF (Salvatore, et al., 2006), there has been a recent interest in
small peptides with neurotrophic-like properties that may offer therapeutic benefit and
avoid delivery limitations (Bradley, et al., 2010; Kelps, et al., 2011).
GDNF and other neurotrophic factors are processed as immature precursor
proteins with a pro-region – absent from the mature secreted GDNF protein (Chao and
Bothwell, 2002). The pro-region is predicted to yield small amidated peptides that have
been investigated by our group and independently by others (Figure 3.1) (Bradley, et al.,
2010; Immonen, et al., 2008; Kelps, et al., 2011). Peptides from the pro-region of
neurotrophic factors (pro-peptides) have been suggested to regulate folding and
secretion of the mature secreted protein (Gray and Mason, 1990), however, evidence for
sequence conservation among related species suggest potential for distinct biological
activity of pro-peptides (Immonen, et al., 2008).
An 11-amino-acid sequence derived from the GDNF pro-sequence in the rat
(Immonen, et al., 2008) and human (Bradley, et al., 2010; Kelps, et al., 2011) (Table 3.1)
has demonstrated biological effects including: 1) enhanced survival and morphological
complexity of primary DA-neuron cell cultures 2) protection from cytotoxicity of 630

hydroxydopamine, staurosporine and gramicidin 3) increased resting extracellular levels
of DA in vivo (Bradley, et al., 2010) and 4) increased excitability of rat CA1 pyramidal
neurons (Immonen, et al., 2008). In the described studies, we further investigated in vivo
biological activity of pro-peptides with particular attention to neurotrophic-like effects in
the nigrostriatal pathway. DNSP-11 was further investigated for enhancing effects in the
nigrostriatal pathway of the F344 rat with the general hypothesis that DNSP-11
enhances dynamic properties of DA-neuron function in the nigrostriatal pathway. A
single treatment of DNSP-11 was administered to the primary cell bodies of the SN and
in vivo electrochemistry was used to measure DA release from discrete striatal subregions at designated time points: 1-, 2-, and 4-weeks after treatment. Thus, these
studies determined if there were heterogeneous effects of DNSP-11 on striatal subregions and when the peak effect of DNSP-11 occurred. Additionally, neurochemical
content of striatal and nigral tissues was investigated to determine if there were
indications for DA-synthesis or -metabolism modulation after DNSP-11 treatment.
The post-translational processing model of GDNF predicts the generation of an
additional 5-amino-acid peptide (Figure 3.1; Table 3.1) termed dopamine-neuron
stimulating peptide-5 (DNSP-5), which has also been examined for biological activity
(Bradley, et al., 2010; Immonen, et al., 2008; Kelps, et al., 2011). DNSP-5 has been
shown to: 1) increase morphological features of DA neurons in cell culture 2) protect
cells from staurosporine-induced cytotoxicity and 3) increase extracellular levels of DA in
vivo (Richardson, 2009; Fuqua, 2010). Because DNSP-11 and DNSP-5 are predicted to
be generated concurrently, both peptides were delivered to the SN and striatal
microdialysis was performed to determine if the peptide mixture enhanced DA-neuron
function – as demonstrated for a single treatment of DNSP-11 or DNSP-5 (Bradley, et
al., 2010; Fuqua, 2010). Striatal and nigral tissues were also collected to determine if
there were changes in DA-synthesis or -metabolism after DNSP-5/-11 treatment.
Materials and Methods

Reagents
DNSP-11 peptides were synthesized and purified by W.M. Keck Foundation
(Yale University, New Haven, CT). DNSP-5 peptides and control peptides were
synthesized and purified to >98% using reverse phase high-pressure liquid
chromatography by AC Scientific (Duluth, GA). The control peptide (scrambled 11mer)
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consisted of identical amino-acid constituents but different sequence than DNSP-11
(Leu-Pro-Ser-Pro-Arg-Glu-Asp-Ala-Glu-Pro-Ala-amide).
Delivery of DNSPs
Peptides were dissolved (4 mM) in sterile (0.22 μM filtered) citrate buffer (10 mM
sodium citrate, 150 mM NaCl, pH = 5) (Bradley, et al., 2010). Peptide and citrate buffer
(vehicle) aliquots were stored at (-80°C). Animals (see Rat Studies) were treated using 2
infusion points just dorsal to the right SN as described in previous studies using GDNF
(Hebert, et al., 1996). A single cranial burr hole was adequate to access both infusion
points. Stereotaxic coordinates from bregma were (mm): Point 1: anterior-posterior: -5.6,
medial-lateral: - 1.7, dorsal-ventral: -7.3; Point 2: anterior-posterior: -5.6, medial-lateral: 2.5, dorsal-ventral: -6.8; incisor bar: -2.3; (Paxinos and Watson, 2005). See also
Intracranial Drug Delivery - Survival Surgical Procedures.
For electrochemical studies, animals were treated with: 1) DNSP-11 (30 µg), 2)
control peptide (30 μg) or 3) citrate buffer vehicle (equivalent volume) (n = 7-9). A total of
5 μL (0.25 μL/min) of solution was delivered to the SN (divided equally between the two
points).
In the microdialysis studies either 1) DNSP-11 (10 μg) + DNSP-5 (10 μg) (equal
mass solution) or 2) citrate buffer (vehicle) (equivalent volume) was administered (n = 4)
using the delivery methods described (Intracranial Drug Delivery - Survival Surgical
Procedures).
Electrochemical Recordings (DNSP-11)
Animals and materials were prepared for electrochemical recordings (In Vivo
Electrochemical Recording and Microdialysis – Non-Survival Surgical Procedures; In
vivo Electrochemistry) at the designated time points after unilateral DNSP-11, vehicle or
control treatment. The glass micropipette was filled with an isotonic potassium chloride
solution (120 mM KCl, 29 mM NaCl, 2.5 mM CaCl2•2H2O, pH =7.2-7.4) used to locally
depolarize striatal terminals (Gerhardt, et al., 1986). The carbon fiber/micropipette
assembly was stereotaxically placed and lowered into the striatum. Stereotaxic
coordinates used were (from bregma (mm)): Site 1: anterior-posterior: 0, medial-lateral: 2.3, dorsal-ventral: -3.5 to -7.5; Site 2: anterior-posterior: +1.0, medial-lateral: -2.3,
dorsal-ventral: -3.5 to -7.5; incisor bar: -2.3 (Paxinos and Watson, 2005) (Figure 3.2).
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After reaching a stable baseline (~1 hour of baseline recording following initial
placement in the brain), the recording assembly was lowered along the dorsal-ventral
axis of the striatum. The potassium solution was locally applied (75-125 nL) (see Local
Application of Solutions In Vivo) to elicit a single DA signal from each recording depth
(500 μm increments; dorsal-ventral: -3.5 to -7.5) (Figure 3.3). When the DA signal had
returned to a stable baseline, the recording assembly was lowered 500 μm to the next
recording depth. Baseline recordings were obtained for a minimum of 5 minutes before
local application of potassium solution at the next recording depth. Because these data
demonstrated greater variability within an individual animal (between recording depths)
than between animals (at the same recording depth), each recording point (depth) was
treated as an individual sample (n) as previously outlined (Cass and Gerhardt, 1994;
Hebert, et al., 1996). Based on the heterogeneity of the origin of DA terminals in the
striatum (Beckstead, et al., 1979) and appreciable variability in amplitude among dorsal
and ventral recording depths (Figure 3.3), data were grouped and analyzed by striatal
sub-region: dorsal, intermediate and ventral. Each sub-region included DA-release data
from three depths: -3.5, 4.0, -4.5 (dorsal), -5.0, -5.5, -6.0 (intermediate), -6.5, -7.0, -7.5
(ventral).
High–speed chronoamperometric data were analyzed using custom MATLAB®based software (The MathWorks™, Inc.). The DA signal amplitudes were quantified as
a transient and robust increase/change (Δ) from the baseline oxidation current (nA). The
change was then divided by the electrode slope (nA/µM) to calculate the concentration
change in DA (μM) (Hebert, et al., 1996) (Figure 2.3; Figure 3.3). All signals used for
analysis exhibited reduction:oxidation ratios of 0.74 ± 0.003 (mean ± SEM), n = 1014
(signals) consistent with the established profile for DA (Gerhardt and Hoffman, 2001).
Microelectrodes used in the described experiments were selective for DA (≥ 99:1, versus
ascorbate), exhibited linear responses to DA (R2 ≥ 0.97) and demonstrated an LOD of
39 ± 6 (nM) using a signal:noise ratio ≥ 3 (mean ± SEM, n = 68, microelectrodes).
Histology
After electrochemical recordings, animals were decapitated while under deep
anesthesia and the brains were dissected and frozen until preparation to cryo-section
(40 μm; Microm, Zeiss, and Thornwood, NY, USA). Sections were mounted on glass
slides,

stained

with

cresyl

violet

acetate
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and

cover-slipped.

Placement

of

microelectrodes within the striatum was examined in histological sections. The observed
recording tracts are shown (Figure 3.2).
Determination of Tissue Neurochemical Content by HPLC-EC
In a separate cohort of animals, neurochemical content of striatal and nigral
tissues were determined for DNSP-11 and vehicle treated animals (4 weeks after
treatment, n = 6-8). Tissues from animals used in microdialysis studies (DNSP-5/-11 and
vehicle) (see Delivery of DNSPs) were also collected for neurochemical analysis.
Animals were euthanized via CO2 asphyxiation and decapitated. Brains were placed in
an ice-cold rat brain matrix and sectioned into 1 mm slices. Based on heterogeneous DA
innervation of the striatum (Swanson, 1982), the treated striata were dissected into
dorsal and ventral sub-regions. The treated SN was also dissected. Samples from the
treated striata and SN were collected and analyzed (see Tissue Preparation and
Neurochemical Analysis of Tissues (HPLC-EC)). Analyses of tissue by HPLC-EC were
performed by Wayne Cass, Ph.D.

Microdialysis
Microdialysis probes (CMA 11, CMA Microdialysis, Stockholm, Sweden; 4 mm
membrane length) were prepared by perfusion with 70% ethanol (3 μL/min) followed by
water (~0.2 μL/min) until probe recovery determination. Before in vivo microdialysis,
probes were calibrated for percent recovery in vitro. Microdialysis probes were
submerged in a standard solution of analytes of interest:
100 nM 3,4-dihydroxyphenylacetic acid (DOPAC)
200 nM dopamine (DA)
100 nM homovanillic acid (HVA)
Probes were perfused with physiological artificial cerebrospinal fluid (aCSF) (1
μL/min) for 20 minutes to collect the probe recovery sample from the standard solution.
Percent recovery for each microdialysis probe was determined for individual analytes
and used to normalize microdialysis data. Microdialysis probe percent recovery ranged
from 22-33% (for DA).
Gastight® syringes (Hamilton USA, Reno, NV; 1000 μL) containing aCSF
solutions were connected to microdialysis probes using Teflon® tubing (FEP tubing, 0.12
mm inner diameter) and tubing adapters (CMA Microdialysis, Stockholm, Sweden). A KD
scientific syringe pump (KDS230, Holliston, MA) was used to control perfusion rate (1
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μL/min). Syringes were connected to a liquid switch (CMA/110, CMA Microdialysis,
Stockholm, Sweden) to alternate aCSF solutions*:
1) physiological aCSF (124 mM NaCl, 3 mM KCl, 1 mM CaCl2•2 H2O, 1
mM MgCl2•6 H2O, 1 mM NaH2PO4•H2O, 25 mM NaHCO3, 5.9 mM
d-glucose)
2) high-potassium aCSF (27 mM NaCl, 100 mM KCl, 1 mM CaCl2•2 H2O,
1 mM MgCl2•6H2O, 1 mM NaH2PO4•H2O, 25 mM NaHCO3, 5.9
mM d-glucose)
(3) d-amphetamine aCSF (250 μM d-amp (Sigma-Aldrich), 124 mM NaCl,
3 mM KCl, 1 mM CaCl2•2 H2O, 1 mM MgCl2•6 H2O, 1 mM
NaH2PO4•H2O, 25 mM NaHCO3, 5.9 mM d-glucose) (pH adjusted
to 7.2-7.4)
*Reagents for aCSF solutions were purchased from Fisher Scientific
All aCSF solutions were gassed (95% O2, 5% CO2) and contained 500 μM ascorbate.
Microdialysis probes were stereotaxically placed in the right striatum (see In Vivo
Electrochemical Recording and Microdialysis – Non-Survival Surgical Procedures) as
described for previous studies using DNSP-11 (Bradley, et al., 2010). Stereotaxic
coordinates were (from bregma (mm)): anterior-posterior: +1.5; medial-lateral: -2.3;
dorsal-ventral: -8.0; incisor bar: -2.3 (Paxinos and Watson, 2005). Artificial cerebrospinal
fluid was perfused through the probes at a rate of 1 μL/min and dialysate samples were
collected at 20-minute intervals (Figure 3.8).
Baseline neurochemical levels were determined from dialysates collected during
perfusion of isotonic (1) aCSF (samples 3-5). Evoked DA release was measured during
perfusion of: (2) high-potassium aCSF (sample 7) and (3) d-amphetamine aCSF (sample
12). Dialysate samples were analyzed by HPLC-EC (see Neurochemical Determination
by HPLC-EC) for DA and its primary metabolites: DOPAC and HVA.
Neurochemical Determination by HPLC-EC (Microdialysis Dialysates)
Quantification of analytes in dialysate samples was done using HPLC-EC
(Beckman, Inc., Fullerton, CA) methods modified from an established protocol for the
detection of catecholamines (Hall, et al., 1989). Briefly, a citrate-acetate buffer mobile
phase was used (4% methanol, 0.34 mM 1-octane-sulfonic acid, pH = 4.05-4.15) at a
flow rate of 1.7 mL/min. Analytes were separated with reverse phase chromatography
using a C18 column (4.6 mm x 75 mm, 3 μm particle size, Shiseido CapCell Pak UG120,
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Shiseido Co., LTD., Tokyo, Japan). Dual-channel coulometric detectors were used for
electrochemical detection (ESA model 5014B dual analytical cell; E1 = +300 mV; E2 = 250 mV, pre-conditioning cell = +100 mV). Standards (see Microdialysis) were used to
determine retention time and concentration based on peak area.

Data Analysis and Statistics
Values > 2 standard deviations from the mean were removed from all data.
Statistical significance was defined as p < 0.05 for all analyses. In reported statistics, n
represents the number of animals unless indicated otherwise.
Results
DNSP-11 Effects on Dopamine Release (In vivo Electrochemical Studies)
Electrochemical methods were used to investigate sub-regional effects on
potassium-evoked DA release within the dorsal-ventral orientation of the striatum. These
studies also examined the duration of effects from a single treatment because
experiments were performed 1-, 2- and 4-weeks after a single unilateral treatment
(DNSP-11, vehicle or control peptide) to the SN. Vesicular DA release was stimulated by
local application of a high-potassium solution and the subsequent release was measured
by high-speed chronoamperometry. Measurements were taken every 500 µm to obtain a
striatal depth profile for DA release at each time point. Depth-profile analysis of the
striatum was conducted comparing DNSP-11 and vehicle treatment for several time
points: 1 week (Figure 3.4), 2 weeks (Figure 3.6), and 4 weeks (Figure 3.7) after
treatment. Control peptide treatment was examined only at the 2-week time point due to
peptide availability.
For all time points, an appreciable decline in amplitude was apparent in more
ventral recording depths compared to dorsal recording regions (Figures 3.4, 3.6, 3.7;
statistical analysis not shown). This decline is consistent with previous studies using the
same methodology (Gerhardt, et al., 1986; Hebert, et al., 1996) and reflects a
corresponding decrease in DA nerve terminal density in the ventral striatum (Oke, et al.,
1978). Of greater interest than the depth variable was the effect of DNSP-11 treatment.
The striatal depth profiles and sub-regional analysis 1- (Figure 3.4) and 4-weeks (Figure
3.7) after treatment did not indicate changes in release amplitude for any recording
depth or striatal sub-region (p > 0.05, all). DNSP-11 treatment did, however,
demonstrate increased DA release 2 weeks after treatment (Figures 3.5, 3.6). A control
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peptide (scrambled 11mer), which became available during these studies, was added as
an additional treatment group to the 2-week studies (Figure 3.5, 3.6). This group was
included to investigate the potential effects of a control peptide on DA release. DNSP-11
treatment increased DA-release amplitude (F2,185= 12.88, p < 0.0001), which occurred at
two individual recording depths in the rostral recording site (AP +1.0) versus the control
peptide (Figure 3.6 A): [mean ± SEM (μM); Dorsal-Ventral: 4.0 mm **p < 0.01, Control:
2.13 ± 0.40; DNSP-11: 4.26 ± 0.84; Dorsal-Ventral: 4.5 mm, **p < 0.01 Control: 2.11 ±
0.30; DNSP-11: 4.46 ± 0.62; n = 8]. There were no significant effects of treatment on
DA-release amplitude (p > 0.05) for any individual recording depth in the caudal (AP 0)
recording site. Sub-regional analysis of the striatum (Figure 3.6 C, D) shows a significant
effect of treatment [AP +1.0: F2,203 = 13.04, p < 0.0001, AP 0: F2,192= 3.13, p = 0.0462] on
amplitude at both recording sites. DNSP-11 increased DA release in the dorsal striatum
[mean ± SEM (μM) AP +1.0: vehicle: 2.77 ± 0.28, n = 23; control: 2.11 ± 0.18, n = 24;
DNSP-11: 4.00 ± 0.44 n = 23, **p < 0.01 versus vehicle; ***p < 0.001 versus control; AP
0: vehicle: 3.47 ± 0.36, n = 23; control: 3.46 ± 0.31, n = 24; DNSP-11: 4.64 ± 0.58, n =
24, *p < 0.05 versus vehicle; *p < 0.05 versus control; n represents the number of
signals] and intermediate striatal sub-regions [mean ± SEM (μM) AP +1.0 control: 1.99 ±
0.20, n = 24; DNSP-11 3.02 ± 0.34, n = 24 *p < 0.05 versus control; n represents the
number of signals].
In summary, the greatest effect of DNSP-11 occurred 2 weeks after treatment
and exhibited selectivity for the dorsal and intermediate regions of the striatum.
Additionally, there were no differences (p > 0.05) in DA-release amplitude between
control peptide and vehicle treatment groups.

DNSP-11 Effects on Tissue Neurochemical Content
To evaluate if DA-synthesis, -storage or -metabolism were affected by DNSP-11,
striatal and nigral tissues were collected and analyzed by HPLC-EC for neurochemical
content. Dopamine, primary metabolites (DOPAC, HVA) and turnover ratios were
unchanged (p > 0.05, all) 4 weeks after DNSP-11 treatment (Table 3.2).

DNSP-5/DNSP-11 Effects on Basal Neurochemical Levels (In vivo
Microdialysis)
Because

DNSP-11

and

DNSP-5

have

demonstrated

increased

basal

concentrations of DA and DA metabolites (Bradley, et al., 2010; Fuqua 2010), in vivo
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microdialysis of the striatum was used to determine if co-injection of DNSP-5 and DNSP11 also enhanced DA-neuron function. Extracellular basal concentrations of DA, DOPAC
and HVA were not changed after DNSP-5/DNSP-11 treatment (p > 0.05, all). Evoked DA
release by d-amphetamine and potassium were not significantly changed (p > 0.05,
both) by DNSP-5/DNSP-11 (Table 3.3).

DNSP-5/DNSP-11 Effects on Tissue Neurochemical Content
To evaluate if DA-synthesis, -storage or -metabolism were affected by coinjection of DNSP-5/-11, striatal and nigral tissues were collected from DNSP-5/DNSP11 treated animals and analyzed by HPLC-EC for neurochemical content (Table 3.4).
There were no changes in DA or DOPAC between vehicle and DNSP-5/DNSP-11
treated striata (dorsal and ventral sub-regions), however, HVA levels were significantly
increased by DNSP-5/DNSP-11 treatment (*p = 0.0362, (dorsal striatum only). A
significant change was seen in the SN after DNSP-5/-11 treatment with increased tissue
levels of DA (*p = 0.0331), DOPAC (*p = 0.0015) and HVA (*p = 0.0270).
Turnover ratios were not changed (p > 0.05) in the striatum or SN by DNSP5/DNSP-11.
Discussion
The major finding of these studies is that DNSP-11 treatment increased evoked
DA release. An increase in depolarization-induced DA release may indicate modulation
of several aspects of DA release: DA transporter function, number and/or size of DA
vesicles, vesicular docking and fusion modulation resulting in altered equilibrium
between vesicular release and cytoplasmic DA concentrations and/or ion-channel
modulation of the depolarization event used to stimulate release (Bark and Wilson, 1994;
Gerhardt, et al., 1986; Gillis, et al., 1996; Rosenmund and Stevens, 1996; Shui, et al.,
1998). Although determining the specific underlying mechanisms of the enhancing
effects of DNSP-11 on DA release is beyond the scope of these studies, increased DA
synthesis/storage is unlikely because neurochemical content of tissues did not indicate
changes in DA or DA metabolites. The electrochemical studies highlight important
similarities between DNSP-11 and GDNF, which both demonstrate increased evoked DA
release in the rat (Hebert, et al., 1996) without a parallel increase in tissue
neurochemical content of DA (Hebert, et al., 1996). Both GDNF and DNSP-11 appear to
enhance DA-neuron function through a presynaptic release mechanism, however, the
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difference in the durational profile and spatial presentation of effects provide distinctions
between GDNF and DNSP-11.
Interestingly, co-injection of 2 pro-peptides (DNSP-5/DNSP-11), predicted to be
generated concurrently, does not affect extracellular DA or DA metabolite levels in the
striatum. Analysis of tissue neurochemical content, however, suggests increased DAsynthesis and -metabolism in the SN. The relationship between cellular pathways and
neurochemical effects associated with different DNSPs and, potentially, GDNF is an
interesting aspect of pro-peptide function to be investigated in future studies.

DNSP-11 Treatment Causes Long-term Changes in Dopamine-Neuron
Function
DNSP-11 increased DA release 2 weeks after a single treatment. The time
course supports a robust effect on synaptic function that suggests plastic changes in the
nigrostriatal pathway (Bezard and Gross, 1998). Long-term changes in synapse
structure may contribute to the observed functional changes. Proposed changes in
synapse structure are supported by previous work that demonstrated increased
morphological differentiation of DA neurons in vitro after DNSP-11 treatment (Bradley, et
al.,

2010).

Bradley

et

al.,

also

reported

a

marked

and

rapid

decline

in

immunohistochemical labeling of DNSP-11 (3 hours after treatment) and near
undetectable levels by 24 hours. Rapid (hours) clearance of DNSP-11 relative to the
presentation of neurochemical effects (weeks) support that DNSP-11 induces long term
changes in DA-neuron function. Such rapid clearance of DNSP-11 in vivo prompted
examination of earlier time points (1- and 2-week). Evidence for increased basal
concentrations of DA and DA metabolites (4 weeks after treatment (Bradley, et al.,
2010)) prompted examination of evoked release at 4 weeks. Unfortunately, the 3-week
time point was not examined in the DNSP-11 studies for direct comparison to GDNF
studies. Although the peak effect on DA release by DNSP-11 (2 weeks) is earlier than
the peak effect seen with GDNF (3 weeks, Hebert, et al., 1996), DNSP-11 and GDNF
exhibit comparable (weeks) long-term effects, which are characteristic of transforming
growth factors like GDNF (Hudson, et al., 1995; Lin, et al., 1993). Thus, the general time
course of enhanced in vivo functional measures after DNSP-11 or GDNF treatment is
comparable (weeks). The rapid (hours) clearance of exogenous DNSP-11 (Bradley, et
al., 2010) contrasts with studies using GDNF that have shown GDNF protein detection 7
days after a single treatment (Lapchak, et al., 1997b). Furthermore, evidence that
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DNSP-11 does not interact with the GFRα1 receptor is another disparity and supports
that DNSP-11 and GDNF do not act through the same receptor (Bradley, et al., 2010).
Although a receptor has not been determined for DNSP-11, the discrepancy of GFRα1receptor preference between GDNF and DNSP-11 strongly supports fundamental
mechanistic differences. Although the subtle differences in functional measures (time
course and sub-regional effects) also support this concept, direct comparison of the
electrochemical functional measures is problematic without inclusion of a GDNF
treatment group in the current studies. Direct comparison of the functional measures
should be considered with caution.
Enhanced Dopamine Release in the Dorsal Striatum Indicates a Selective
Effect on the Substantia Nigra
Importantly, these studies indicate that treatment with an 11-amino-acid control
peptide, with identical composition but different sequence than DNSP-11, does not affect
DA release. Additionally, the control peptide did not exhibit different neurochemical
effects versus vehicle treatment (citrate buffer only). Electrochemical studies designed to
characterize evoked DA release in discrete striatal sub-regions indicated significant
increases in evoked DA release in the dorsal striatum of DNSP-11 treated animals (AP
+1.0: 44% increase versus vehicle, 90% versus control peptide; AP 0: 33% versus
vehicle, 34% versus control) and the intermediate striatal sub-region (52% increase
versus control peptide). These studies suggest that the effect on DA terminals in the
striatum is highly selective for A9 nigrostriatal DA projections, which project primarily to
the dorsal striatum (Dunnett, et al., 2005). The spatial presentation of the effects of
DNSP-11 contrasts previous studies reported by Hebert et al., (1996) using GDNF,
which showed a uniform increase in DA release at 8 of the 9 recording depths. While the
effects of GDNF appear to involve both nigrostriatal (A9) and mesolimbic (A10) DA
projections (Dunnett, et al., 2005), DNSP-11 appears to be selective for DA terminals of
the dorsal striatum. The pattern of enhanced DA release by DNSP-11 is of interest in the
context of PD where DA levels are depleted most severely in the human putamen
(Bernheimer, et al., 1973; Hornykiewicz, 1975; Hornykiewicz, 1998; Hornykiewicz, 2002)
– the analogous sub-region to the dorsal striatum in rodents (Joel and Weiner, 2000).
Additionally, the spatial exclusivity of the enhancing effects of DNSP-11 raises the
possibility that previous reports of increased basal DA and DA-metabolite concentrations
measured by microdialysis – using a microdialysis probe that samples from nearly the
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entire striatum (Bradley, et al., 2010) – are underestimated (if the effect of DNSP-11 on
basal DA neurochemistry is also restricted to the dorsal striatum). Also, we would expect
the effects on basal neurochemistry (measured at 4 weeks, (Bradley, et al., 2010)) to be
greater at the 2-week time point because the current release studies demonstrate that 2weeks is the peak effect. Although correlation between evoked release and basal
neurochemistry is apparent for GDNF (Hebert, et al., 1996), this relationship has not
been determined for DNSP-11. A trend in increased release at 4-weeks is not evident in
any striatal sub-region after DNSP-11 treatment. However, the increased sensitivity of
microdialysis (nanomolar) versus the electrochemical release studies (micromolar) may
contribute to the discrepancy. Notably, these techniques examine distinct biological
processes that should be acknowledged: tonic release (microdialysis – basal levels) and
phasic release (electrochemistry – evoked release). Integrating previous studies with the
current release data raises important questions about the resulting changes in DAneuron function after DNSP-11 treatment. It is unclear if changes in basal
neurochemistry (DA and metabolites) precede changes in evoked DA release or if these
effects are mutually exclusive.
The increase in DA release is a substantial finding that supports functional
changes in DA neurons in vivo. We believe this finding is relevant because DA levels are
markedly reduced in PD (Bernheimer, et al., 1973). Alternatively, enhanced release in
the dorsal striatum may be interpreted as merely a consequence of experimental design
– using stereotaxic coordinates targeting the SN (see Delivery of DNSPs). However,
distribution studies using DNSP-11 and this treatment protocol have demonstrated
diffusion of DNSP-11 to the SN as well as the ventral tegmental area (VTA) (Gash et al.,
unpublished), making potential effects of DNSP-11 achievable at both dopaminergic
nuclei. Additionally, this infusion method was used previously with GDNF and resulted in
a uniform increase in evoked DA at nearly all recording regions of the striatum –
supporting modulation DA projections from the VTA and SN (Beckstead, et al., 1979;
Bentivoglio and Morelli, 2005; Hebert, et al., 1996). Although distribution studies of
GDNF using these methods were not conducted, we predict the larger size and heparinbinding characteristics of GDNF would cause decreased diffusion compared to DNSP-11
(Kelps, et al., 2011; Piltonen, et al., 2009; Salvatore, et al., 2006). Thus DNSP-11
appears to selectively enhance DA release in projections corresponding to the SN
despite distribution to adjacent dopaminergic nuclei (the VTA).
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The enhanced release phenomena in the striatal sub-region most closely
associated with motor function (Bernheimer, et al., 1973; Joel and Weiner, 2000)
suggests that DNSP-11 may influence (enhance) locomotor activity. We propose that
regional effects of DNSP-11 at dorsal dopaminergic terminals in the striatum reflect a
differential effect of DNSP-11 at the cell bodies from which these terminals originate. In
particular, these results suggest the SNc is the primary target of DNSP-11 based on
specific projections to the dorsal striatum (Beckstead, et al., 1979; Dahlstrom and Fuxe,
1964a; Ungerstedt, 1971), making it a particularly interesting candidate for PD therapy.
In contrast, the ventral striatum receives more innervation from the VTA (Beckstead, et
al., 1979; Swanson, 1982), where effects of DNSP-11 are not seen at the 2-week time
point. These studies cannot directly correlate motor behavior improvements to DNSP-11
treatment based on selectivity of DNSP-11 effects to the motor striatum. Indeed,
measures of spontaneous locomotor behavior do not indicate significant changes after
DNSP-11 treatment (Fuqua, 2010). Despite the lack of changes in motor activity, we
believe DNSP-11 has the potential to modulate motor function. Because non-lesioned
F344 rats do not exhibit motor impairments for the age group and parameters used in
these studies (Hebert and Gerhardt, 1998), behavioral endpoints would be more
appropriately examined in a model with a behavioral deficit. For example, in rats with 6hydroxydopamine lesions, DNSP-11 has shown improved neurochemical function with
corresponding behavioral improvement (Bradley, et al., 2010). Thus, the behavioral
significance of DNSP-11 should be further examined in systems with a neurochemical
deficiency of the nigrostriatal pathway and a corresponding behavioral deficit.

DNSP-5/DNSP-11 Combination Treatment Enhances Tissue Neurochemical
Content but not Extracellular Levels
Because the post-translational processing model of GDNF predicts DNSP-11
and DNSP-5 are generated simultaneously, neurochemical studies were conducted to
determine if treatment with a 2-peptide mixture (DNSP-5 + DNSP-11) demonstrated
biological effects in vivo. Extracellular basal levels of DA, DOPAC and HVA were not
changed by DNSP-5/DNSP-11 treatment (p > 0.05, all). Interestingly, the peptide mixture
increased tissue levels of DA, DOPAC and HVA (69%, 207%, and 52%, respectively
versus vehicle) in the SN and decreased (23%) tissue levels of HVA in the dorsal
striatum. These experiments were designed to reproduce previous studies using a 3peptide mixture (10 μg each: DNSP-5 + DNSP-11 + DNSP-17), which contained an
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additional 17-amino-acid peptide (DNSP-17) derived from the pro-region of GDNF
(Fuqua, 2010; Kelps, et al., 2011). The 3-peptide mixture increased basal extracellular
levels of DA, DOPAC and HVA and also increased TH-positive fiber density in the SN.
The basal neurochemical and histological findings were not accompanied with changes
in tissue neurochemical content (Fuqua, 2010). We would predict an increase in DAneuron fiber density in the SN to underlie the increases in DA and metabolites in the
DNSP-5/DNSP-11 studies based on findings with the 3-peptide mixture. The
discrepancy in results from the 2- and 3-peptide mixtures suggests diverse signaling and
likely distinct cellular mechanisms among the three related peptides. Based on
association with metabolic proteins (Bradley, et al., 2010), the cellular mechanism(s)
linked to DNSP-11 are suspected to involve mitochondrial function. However, different
mechanisms are suggested for the other DNSPs (Kelps, et al., 2011). Distinct cellular
mechanisms are supported by the lack of intermolecular interaction among the three
peptides in vitro and variable protection from mitochondrial toxins (staurosporine and 3nitropropionate) (Kelps, et al., 2011) among the three peptides. Conceivably, the actions
of the DNSPs (in combination or alone) may also be modulated by GDNF, a possibility
requiring further investigation.
As described above, DNSP-5 and DNSP-11 are believed to act independently
(Kelps, et al., 2011). The dose used for co-injection of DNSP-5 and DNSP-11 should be
reconsidered because an equal mass solution (DNSP-5 + DNSP-11) contains a
disproportionate number of each peptide. It is possible that DNSP-5 acts by an
unidentified negative feedback mechanism, opposing the effects of DNSP-11. The
effects of the peptide mixture may be more appropriately investigated using an equal
molar solution. However, neurochemical effects on extracellular neurochemistry (without
changes in tissue content) are apparent using the same dose in the 3-peptide mixture
(Fuqua, 2010), suggesting an important role of the 17-amino-acid peptide. The specific
cellular actions of the peptides (individual and combinations) are largely speculative at
this time.
Neurochemical Effects of DNSPs Support Unique Function of Pro-peptides
To our knowledge DNSP-11 is the first neurotrophic factor-derived pro-peptide to
be investigated for neurotrophic actions to this extent. Trophic-like effects of propeptides are predicted because pro-peptides have been implicated in cell survival
pathways (Ibanez, 2002; Lee, et al., 2001). Interestingly, uncleaved neurotrophins (e.g.
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pro-BDNF) have been associated with the induction of apoptotic pathways. By contrast,
the cleaved neurotrophin (BDNF) induces cell survival- and differentiation-pathways
(Teng, et al., 2005). The function of pro-BDNF may also be modulated by the proteolytic
processing of a different neurotrophin – NGF (Dicou, 2006; Dicou, et al., 1997). Thus
processing of particular neurotrophins may not only determine the cellular pathway(s)
activated but may also regulate activity of other (different) neurotrophins. These findings
further substantiate the importance of post-translational processing and suggest possible
interactions between neurotrophins and pro-neurotrophins.
The biological activity of the DNSPs, pro-peptides, is particularly interesting in the
context of differential splicing of GDNF. There are two known isoforms of GDNF with one
isoform containing a truncated (26-amino-acid) pro-region (Grimm, et al., 1998). Uncleaved (pro-GDNF) and mature forms of both isoforms have demonstrated distinct
cellular localization. In addition, secretion of the individual isoforms demonstrates
differential modulation by neuronal activity (Lonka-Nevalaita, et al., 2010). In the context
of the presented studies, which show effects on depolarization-induced release after
DNSP-11 treatment, the action of pro-peptides on neuronal activity merits further
investigation to determine the relationship, if any, between neuronal activity and proGDNF processing and secretion. In summary, post-translational processing of proproteins and the resulting generation of multiple bioactive peptides may activate diverse
signaling cascades (Bernay, et al., 2009; Haskins, et al., 2004) that may be interrelated.
Applied to the present findings, we expect further investigation of signaling pathways
may reveal activation of converging pathways associated with cell survival and
differentiation (Ibanez, 2002; Lee, et al., 2001) that are initiated distinctly by the DNSPs
and GDNF (Bradley, et al., 2010; Kelps, et al., 2011).
DNSP-11 is the first peptide from the prodomain of the GDNF family to
demonstrate in vivo trophic-like actions with potential therapeutic value in treating
neurodegenerative disease (Bradley, et al., 2010; Immonen, et al., 2008). The
comparably long–lasting effect (weeks) of a single administration of DNSP-11 is
promising given plasma levels of current PD therapies like L-DOPA peak within one hour
(Adamiak, et al., 2010; Harder and Baas, 1998) and are largely unsuccessful in treating
underlying disease pathology/progression (Kempster, et al., 2007; Marsden and Parkes,
1977). Although the symptomatic relief provided with PD drug therapies may be
sustained for weeks after drug withdrawal (Fahn, et al., 2004), the majority of patients
undergoing chronic L-DOPA therapy experience undesirable side effects like
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dyskinesias along with reduced efficacy within a few years after starting treatment
(Ahlskog and Muenter, 2001; Rajput, et al., 2002). Because dyskinetic side effects have
been attenuated with trophic factor treatment in animal models (Costa, et al., 2001;
Iravani, et al., 2001), the molecular and cellular changes that are suspected to underlie
problems with chronic medical treatment (Nutt, 2003; Obeso, et al., 2000) may be
appropriate targets for DNSP-11 treatment. Thus, in addition to the trophic-like,
potentially disease-progression modifying effects of DNSP-11, DNSP-11 may be a
valuable adjunct therapy to extend the effective therapeutic window for existing medical
treatments.
Conclusions
Although pro-peptides were previously thought to function only to assist in the
processing and secretion of the mature neurotrophin (Rattenholl, et al., 2001), these
studies support specific trophic-like effects on the nigrostriatal pathway. In conclusion,
the use of DNSP-11 and/or related peptides could advance the treatment of
neurodegenerative disease markedly by preventing neuronal loss and/or restoring
function of damaged neurons (Grondin and Gash, 1998; Lapchak, et al., 1997a;
Peterson and Nutt, 2008). Because of their relative size and less complex structure,
DNSP-5, DNSP-11 and other small peptides with trophic-like actions may provide
specific advantages over larger molecules including: ease of synthesis and long-term
storage, improved biodistribution/lack of heparin binding (Kelps, et al., 2011) and
potential for enhanced bioavailabilty and/or modification to allow alternative (less
invasive) delivery routes (Bespalov and Saarma, 2007). The possibility for alternative
administration routes provides substantial advantages over treatment regimens required
for GDNF and other neurotrophic factors, which involve intracranial delivery by pump or
gene therapy approaches (Bjorklund, et al., 2000; Gill, et al., 2003; Grondin, et al., 2002;
Patel and Gill, 2007). These studies demonstrate the neurotrophic-like functional
properties of DNSP-11 and suggest that the DNSPs may be one of many overlooked
groups of bioactive pro-peptides that merit continual examination and evaluation for
potential therapeutics. With favorable physical and physiological properties, further
studies

are

warranted

to

evaluate

DNSPs

as

therapeutic

neurodegenerative diseases like PD.
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Chapter Three: Figures

Figure 3.1 Post-translational Processing Model of GDNF
The pre-pro-GDNF molecule is shown (not drawn to scale) where the peptides of
interest, DNSP-5 and DNSP-11, originate from pro-region (gray). After cleavage of the
signal sequence (blue), a series of enzymatic reactions on the pro-GDNF sequence
(gray) are predicted to occur in vivo. The actions of specific endopeptidases cleave the
pro-protein region at C-terminal, paired-basic amino-acid (++) residues. The resulting
pro-proteins undergo further processing at the C-terminal regions. The actions of
carboxypeptidase H and peptidylglycine amidating monooxygenase (PAM) yield DNSP-5
and DNSP-11 – both amidated at the C-terminus. Modified from Bradley et. al., 2010.
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Figure 3.2 Microelectrode Placement in the Rat Striatum
The figures are representative of the observed recording sites corresponding to
stereotaxic coordinates (A). Two striatal recording sites were used for electrochemical
recordings (from bregma (mm)): Site 1 (rostral site) and Site 2 (caudal site). One DA
signal was elicited at 500 μm increments along the dorsal-ventral axis of the striatum for
each recording site in the treated (right) hemisphere. Histological sections prepared after
electrochemcial recordings are shown (B). The most clearly identified portion of the
electrode tract is indicated (arrow). Because of minimal tissue disruption using a small
recording electrode (~30 μm o.d.), the most ventral placement of the electrode could not
be visualized in all brain slices.
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Figure 3.3 Evoked Release of Dopamine in the Rat Striatum
A potassium chloride solution is applied locally (120 mM, arrow) to elicit one DA signal
every 500 μm along the dorsal-ventral axis of the striatum. The amplitude is calculated
as the change from baseline for each signal. Dopamine release may be very
heterogeneous in the striatum because of differences in DA terminal density. Inset: axes
units.
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Figure 3.4 Striatal Depth Profiles of Evoked Dopamine Release - 1 Week after
Treatment
Using carbon-fiber microelectrodes with high-speed chronoamperometry, measurements
of DA release from local application of potassium were taken. One DA signal was
elicited at 500 µm increments in the rat striatum. The average DA-signal amplitude from
2 striatal recording sites is shown for DNSP-11 and vehicle treated animals (A)(B). The
DA-signal amplitudes from 3 recording depths were combined to determine the mean
release amplitude for striatal sub-regions (C)(D) (dorsal, intermediate and ventral). There
were no statistically significant differences in signal amplitude between treatment groups
for any of the recording depths or striatal sub-regions. Data are shown as mean ± SEM.
All data were analyzed using a two-way ANOVA with Bonferroni’s post hoc tests.
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Figure 3.5 Evoked Dopamine Release is Increased – 2 Weeks after DNSP-11 Treatment
Representative traces of DA-release amplitude in the dorsal striatum evoked by local
application of potassium (arrow) are shown. Vehicle, Control and DNSP-11 treatment
groups are shown 2 weeks after a single intranigral treatment (inset: axes units). DNSP11 treatment (red) increased the amplitude of DA release compared to vehicle (open)
and control (blue) treated animals.
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Figure 3.6 Striatal Depth Profiles of Evoked Dopamine Release - 2 Weeks after
Treatment
Using carbon-fiber microelectrodes with high-speed chronoamperometry, measurements
of DA release from local application of potassium were taken. One DA signal was
elicited at 500 µm increments in the rat striatum. The average DA-signal amplitude from
2 striatal recording sites is shown for DNSP-11, control and vehicle treated animals
(A)(B). A significant effect of treatment was observed in the rostral (AP+1.0) recording
site (A). Post hoc analysis indicates a significant increase in DA release in DNSP-11
treated groups versus the control peptide at two individual recording depths in the
striatum (A) [DV: 4.0 mm, **p < 0.01, DV: 4.5 mm, **p < 0.01, n = 8]. The DA signal
amplitudes from 3 recording depths were combined to determine the mean release
amplitude for striatal sub-regions (C)(D) (dorsal, intermediate and ventral; n = number of
signals). There was a significant effect of treatment in both striatal recording sites. In the
rostral recording site (C) post hoc analysis confirms a significant increase in amplitude in
DNSP-11 treated groups versus vehicle (**p <0.01, n = 23) and control peptide (***p <
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0.001, n = 23-24) in the dorsal striatum. In the intermediate striatum, there was also a
significant increase (*p < 0.05, n = 23-24) in amplitude in DNSP-11 treated groups
versus control peptide. In the caudal recording site (D) post hoc analysis indicates a
significant increase in amplitude in DNSP-11 treated groups (n = 24) in the dorsal
striatum versus vehicle (*p < 0.05, n = 23) and control (*p < 0.05, n = 24). Data are
shown as mean ± SEM. All data were analyzed using a two-way ANOVA with
Bonferroni’s post hoc tests.
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Figure 3.7 Striatal Depth Profiles of Evoked Dopamine Release - 4 Weeks after
Treatment
Using carbon-fiber microelectrodes with high-speed chronoamperometry, measurements
of DA release from local application of potassium were taken. One DA signal was
elicited at 500 µm increments in the rat striatum. The average DA-signal amplitude from
2 striatal recording sites is shown for DNSP-11, and vehicle treated animals (A)(B). The
DA signal amplitudes from 3 recording depths were combined to determine the mean
release amplitude for striatal sub-regions (C)(D) (dorsal, intermediate and ventral). There
were no statistically significant differences in signal amplitude between treatment groups
for any of the recording depths or striatal sub-regions. Data are shown as mean ± SEM.
All data were analyzed using a two-way ANOVA with Bonferroni’s post hoc tests.
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Microdialysis of the Striatum
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Figure 3.8 In Vivo Microdialysis after DNSP-5/-11 Treatment
Basal extracellular levels of DA (shown) and DA metabolites were determined by striatal
microdialysis following intranigral DNSP-5/-11 or vehicle treatment. Microdialysis
samples were collected at 20-minute intervals. The average of three samples was
calculated to determine basal levels of DA and DA metabolites. High-potassium (K+) and
d-amphetamine (D-Amp) aCSF solutions were used to stimulate DA release. Data are
shown as mean ± SEM.
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Table 3.1 DNSP-11 and DNSP-5 Sequences

DNSP-11 and DNSP-5 sequences are highly conserved among related species. Both
peptides are generated through the predicted post-translational processing of the proregion of GDNF.
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Table 3.2 Tissue Neurochemical Content after Treatment with DNSP-11

Data shown as mean ± SEM (ng/g wet weight of tissue). Analyzed by a two-tailed
unpaired t test comparing treatment groups.

56

Table 3.3 Extracellular Levels of Dopamine and Metabolites after Treatment with Peptide
Mixture (DNSP-5 and DNSP-11)

Data shown as mean ± SEM (nM). Analyzed by a two-tailed unpaired t test comparing
treatment groups.
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Table 3.4 Tissue Neurochemical Content after Treatment with Peptide Mixture (DNSP-5 and DNSP-11)

Data shown as mean ± SEM (ng/g wet weight of tissue). Analyzed by a two-tailed unpaired t test comparing treatment
groups.
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Chapter Four: Dynamic Changes in Nigrostriatal Dopamine-Neuron
Function in Gdnf+/- Mice – A Novel Model of Nigrostriatal Dysfunction
Introduction
The decline in motor function associated with aging has been demonstrated in
animal models of aging (Hebert and Gerhardt, 1998; Willig, et al., 1987; Yurek, et al.,
1998; Zhang, et al., 2000) and parallels a similar decline in human aging (Bennett, et al.,
1996; Kluger, et al., 1997; Richards, et al., 1993). Dopamine-neuron dysfunction has
been linked to age-associated motor impairment in humans (Volkow, et al., 1998b) and
animals (Gerhardt, et al., 2002; Hebert and Gerhardt, 1998; Yurek, et al., 1998). The
loss of functional DA neurons in the SNc and consequent loss of striatal DA are
hallmarks of PD (Marsden, 1990), which presents with cardinal motor symptoms:
bradykinesia, rigidity, postural instability and tremor (Hornykiewicz and Kish, 1987;
Parkinson, 2002). The presence of some of these deficits is observed in many aged
individuals and has been termed “age-associated parkinsonism” (Bennett, et al., 1996),
which likely involves changes in the functional properties of DA neurons rather than
marked neuronal loss as demonstrated in aged rats and non-human primates (Grondin,
et al., 2003; Hebert and Gerhardt, 1999; Hebert, et al., 1999; Yurek, et al., 1998).
Glial cell line-derived neurotrophic factor (GDNF) is a distant member of the
transforming growth factor- superfamily (Lin, et al., 1993). It is hypothesized that agerelated decreases in neurotrophic factor levels contribute to DA-neuron degeneration
and/or dysfunction (Yurek and Fletcher-Turner, 2001). In vivo application of exogenous
GDNF to the SN has been reported to enhance DA-neuron function in young (Hebert, et
al., 1996), aged (Grondin, et al., 2003; Hebert and Gerhardt, 1997) and lesioned (Hoffer,
et al., 1994; Tomac, et al., 1995) animals. In addition, GDNF protects and restores DAneuron function related to neurotoxic doses of methamphetamine in rats (Cass, et al.,
2000; Cass, et al., 2006) and restores function in rhesus monkeys with MPTP-induced
parkinsonism (Gash, et al., 1996; Grondin, et al., 2002). Treatment with GDNF has also
been shown to enhance DA-neuron function indicated by increased: 1) evoked DA
release 2) locomotor behavior 3) DA content in nigral tissue (Hebert and Gerhardt, 1997;
Hebert, et al., 1996) and 4) high-affinity DA uptake (Lin, et al., 1993). However, the exact
role(s) of GDNF in normal aging, specifically the maintenance of DA-neuron function, is
not known.
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At birth, midbrain DA systems in mice homozygous for the GDNF null mutation
(Gdnf-/-) appear normal (Moore, et al., 1996), however, function of these neurons after
major apoptotic waves (occurring 2 and 14 days after birth) (Mahalik, et al., 1994) cannot
be assessed because these mice die at birth due to kidney agenesis (Moore, et al.,
1996). Therefore, postnatal in vivo studies have used mice with a partial deletion of the
Gdnf gene (Gdnf+/-) (Pichel, et al., 1996), which exhibit a partial and stable reduction of
GDNF protein in brain tissues (Boger, et al., 2006). GDNF expression in the striatum
appears to be critical for the survival and differentiation of midbrain DA neurons and
innervation of striatal targets during early development (Stromberg, et al., 1993). Indeed,
postnatal development of these DA neurons is compromised in the absence of GDNF
(Granholm, et al., 2000). Behavioral and immunohistochemical characterization in
multiple age groups (4-, 8-, 12-, 16- and 20-month-old) provides evidence for a unique
aging phenotype in the Gdnf+/- mice. A partial GDNF depletion leads to an earlier loss of
TH-positive neurons in the SNc and diminished spontaneous locomotor activity at 12
months of age (Boger, et al., 2006). The diminished locomotor activity and decline in THpositive neurons also demonstrate an accelerated decline with age (between 8 and 12
months) in the Gdnf+/- mice. By contrast, both measures in WT mice of the same age
groups are unchanged (Boger, et al., 2006) and young Gdnf+/- mice (6 to 9-month-old) do
not exhibit changes in spontaneous or methamphetamine-induced locomotor behavior
(Boger, et al., 2006; Boger, et al., 2007; Gerlai, et al., 2001). In vitro studies using
synaptosomal preparations from Gdnf+/- mice indicate increased DAT activity that has
been suggested to predispose DA neurons to methamphetamine-induced toxicity
(Boger, et al., 2007). Consistent with the age-related changes in DA systems noted
above, DAT activity in the nigrostriatal pathway is altered in the normal aging process in
animal models (Friedemann, 1992; Friedemann and Gerhardt, 1992; Hebert and
Gerhardt, 1999; Hebert, et al., 1999) and may be correlated with age-related motor
deficits. Dynamic changes in DA uptake have been characterized by in vivo
chronoamperometry using carbon fiber microelectrodes and parameters associated with
DAT activity (Cass, et al., 1993; Gerhardt, et al., 1999; Gerhardt, et al., 1986). The high
spatial (microns) and temporal (seconds) resolution (Gerhardt and Hoffman, 2001) of
this electrochemical technique allows for the rapid and sensitive quantification of DA
uptake in discrete DA-terminal sub-regions.
Based on in vitro studies that indicate DA uptake in Gdnf+/- mice was increased
compared to WT mice (Boger, et al., 2007), the present study investigated this age60

associated abnormality by using in vivo electrochemistry to examine the effects of a
partial and chronic genetic reduction of GDNF on the function of DA terminals in the
striatum of middle-aged (12-month-old) Gdnf+/- mice. Additionally, because GDNF
supplementation has been shown to enhance DA release in the rat and non-human
primate (Grondin, et al., 2003; Hebert and Gerhardt, 1997; Hebert, et al., 1996), DA
release in middle-aged Gdnf+/- mice was investigated. The following questions were
addressed: (1) Do Gdnf+/- mice differ in behavioral response to DAT modulation via DAT
inhibition? (2) Do Gdnf+/- mice exhibit altered DA-clearance and -release properties in
vivo and what is the spatial pattern of this effect within striatal sub-regions? (3) Do
Gdnf+/- mice have altered striatal DA-receptor expression? (4) Is whole tissue
neurochemical content altered in Gdnf+/- mice?
Collectively, these studies focus on the functional properties of DA neurons in 12month-old Gdnf+/- mice, which demonstrate accelerated age-related motor deficits and
loss of TH-positive neurons (Boger, et al., 2006), with the hypothesis that GDNF
depletion causes in vivo alterations in DA-neuron function that contribute to locomotor
function.
Materials and Methods
Electrochemical Recordings
For electrochemical recordings, Gdnf+/- (n = 5) and WT littermates (n = 7) were
prepared as described (see In Vivo Electrochemical Recording and Microdialysis – NonSurvival Surgical Procedures).
The microelectrodes used for electrochemical recordings were prepared (see In
vivo Electrochemistry) and chronoamperometric measures were carried out as described
previously (See Chronoamperometry). Calibration of microelectrodes confirmed linear
responses to serial additions of DA (2 – 6 μM, effective beaker concentrations) with
correlation coefficients (R2) ≥ 0.99. Selectivity of the electrodes for DA (versus
ascorbate) averaged 908:1 ± 166 (n = 13). The LOD (nM) for DA was 11 ± 3 (n = 13)
with a signal to noise ratio ≥ 3. Calibration parameters are expressed as mean ± SEM, n
= number of electrodes.
Two striatal recording sites per hemisphere were used to determine DA-uptake
and -release characteristics. Stereotaxic coordinates from bregma were (mm): Site 1
(rostral-medial): anterior-posterior +1.0, medial-lateral +/- 1.2, dorsal-ventral -3.0 to -4.6;
Site 2 (caudal-lateral): anterior-posterior +0.1, medial-lateral +/- 2.2, dorsal-ventral -2.5
61

to -4.1 (incisor bar positioned with lambda level to bregma; Figure 4.1) (Franklin and
Paxinos, 2001). The electrode recording assembly was stereotaxically placed into the
targeted striatal recording sites. The recording assembly was lowered at 400 μM
increments through the dorsal-ventral orientation of the striatum. Dopamine uptake
characteristics were determined by local application (see Local Application of Solutions
In Vivo) of DA solution (100 μM DA, 200 μM ascorbate, in 0.9% NaCl) at each depth in
the left hemisphere. Dopamine release was investigated similarly, by local application of
potassium solution (120 mM KCl, 29 mM NaCl, 2.5 mM CaCl2•2H2O) (Gerhardt, et al.,
1986) in the right hemisphere.
After initial placement of the microelectrode/micropipette assembly in the brain,
cortical baseline recordings were conducted for a minimum of 1 hour. The recording
assembly was then lowered to the targeted recording area in the striatum for studies of
DA-uptake and -release. Signals analyzed for DA release were volume matched (75-150
nL) for the amount of potassium solution applied. For DA uptake studies, the solution
volume was adjusted and recorded in order to obtain DA signals of equivalent
amplitudes, which were analyzed for clearance kinetics (Cass and Gerhardt, 1995;
Cass, et al., 1993). In both the release and uptake studies, a single DA signal was
elicited at several depths along the dorsal-ventral orientation of the striatum. When the
signal had returned to a stable baseline, the recording assembly was lowered 400 μm to
the next recording depth. Baseline recordings were collected for a minimum of 5 minutes
before local application of solution at the next recording depth. All DA signals used for
analysis exhibited mean reduction:oxidation ratios consistent with the established profile
for DA (mean ± SEM; DA uptake studies: 0.78 ± 0.01 (n = 107), DA release studies:
0.779 ± 0.01 (n = 98); n = number of signals) (Gerhardt and Hoffman, 2001; Gerhardt,
et al., 1986).
Analysis of Electrochemical Recordings
Several signal parameters obtained from individual DA signals were analyzed
(Figure 4.2). High–speed chronoamperometric data were analyzed using custom
MATLAB®-based software (The MathWorks™, Inc.). Signal amplitude was calculated
as the current change (Δ) from baseline after local application of solutions. The change
in current can be divided by the calibration slope to determine the effective change in DA
in concentration units: μM (release studies) or nM (uptake studies). Signal amplitude
was calculated for both uptake and release studies and was the primary parameter of
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interest in the release studies. In the DA uptake studies, the first order exponential decay
constant, k-1 (sec-1), was calculated from the decay portion of the signal fitted to the
slope of the linear regression of the natural log transformation of the data (Sabeti, et al.,
2002). The first order decay constant, k-1 (sec-1), is a quantitative measure that can be
multiplied by the signal amplitude (nM) to yield the uptake rate (nM/sec) (Stephens, et
al., 2009). For our purposes, we analyzed only the k-1 because signal amplitudes were
matched. A single value for k-1 was obtained using one signal from each recording depth
using signal amplitudes that were matched (Cass, et al., 1992; Cass, et al., 1993). The
volume of solution applied to obtain signals with amplitudes ranging from 500-1000 nM
was recorded and used to calculate the total amount (pmol) of DA applied. Adjusting the
volume of DA applied enables modulation of signal amplitude such that physiologically
appropriate concentrations are analyzed and the inherent Michaelis-Menten properties
of the DAT are not altered by varied extracellular concentrations of substrate (Hebert
and Gerhardt, 1999).

In addition, the DA signal amplitude (nM) per amount of DA

applied (pmol) (Figure 4.2) is a measure that reflects surface expression of the DAT
(Cass and Gerhardt, 1995; Hebert and Gerhardt, 1999). Because prior work
demonstrated heterogeneous properties of DA uptake and DAT density, which varies
most notably along the dorsal-ventral orientation of the striatum (Hebert and Gerhardt,
1999; Hebert, et al., 1999), uptake data (k-1 and amplitude per picomole DA applied)
from the striatum were divided and analyzed using dorsal and ventral sub-regions at
each recording site. Five recording depths separated by 400 μm were used in each
recording site. For each animal, data from the two most dorsal recording depths were
used to characterize the dorsal striatum (Str) (sites 1 and 2) and the two most ventral
sites were used similarly to characterize the ventral striatum/nucleus accumbens (NAc)
of the rostral-medial recording site (site 1) or ventral Str of the caudal-lateral recording
site (site 2). Data from DA-release studies were grouped similarly based on
heterogeneous DA innervation of the striatum (Fallon and Moore, 1978b; Lindvall and
Bjorklund, 1974). Data from the dorsal and ventral sub-regions of all animals were
combined, averaged and analyzed by a two-tailed unpaired t test to compare differences
at the same recording sub-region between genotypes. Data from the respective dorsal
and ventral sub-regions remained separated by recording site.
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Histology
After electrochemical recordings, animals were decapitated under deep
anesthesia and the brains were dissected for histological studies to confirm electrode
placement in the striatum (see Histology). The observed electrode placement in the
striatum is shown (see Figure 4.1).

Semi-Quantitative In Situ Hybridization Histochemistry
These studies were conducted at the Medical University of South Carolina by
Heather Boger, Ph.D. Semi-quantitative in situ hybridization of the DA D2 receptor was
performed on Gdnf+/- (n = 4) and WT mice (n = 6) as previously described (Wang and
McGinty, 1995). Striatal sections were cryo-sectioned (12 μm) and mounted on
Superfrost/Plus slides (Fisher Scientific, Pittsburgh, PA, USA). Sections were pretreated
to fix and defat the tissue and block non-specific hybridization. A 1:1 mixture of synthetic
cDNA oligodeoxynucleotide probes, complementary to the long form of D2 receptor
mRNA (D2244; corresponding to bases 728-763) and the short form of D2 receptor mRNA
(D2415; corresponding to bases 704-739), was labeled using alpha-[35S]-dATP
(Amersham Biosciences, Piscataway, NJ, USA) and terminal deoxynucleotidyl
transferase (Roche Diagnostics Corporation, Indianapolis, IN, USA). Sections were
immersed in 5.0 x 105 cpm/20 mL hybridization buffer per section overnight (15 hours) at
37oC in a humid environment. Sections were washed and air dried before being placed
into a film cassette with 14C standards (American Radiolabeled Chemicals, St Louis, MO,
USA) and Kodak Biomax film (Rochester, NY, USA) for 2 weeks. Quantitation of the
mRNA hybridization signals was performed using NIH image 1.62 software as previously
described (Wang and McGinty, 1995).
Immunoblotting
These studies were conducted at the Medical University of South Carolina by
Heather Boger, Ph.D. Striatal samples (20 μg) from 12-month-old WT and Gdnf+/- mice
(n = 4) were loaded in duplicate and separated on 4-12% NuPAGE Bis Tris gels
(Invitrogen, Carlsbad, CA) at 150V for 45 minutes. After separation onto the gel, the gel
was transferred via wet transfer onto a nitrocellulose membrane for one hour at 30 V.
The membrane was then removed from the cassette and blocked for one hour in 5%
non-fat milk in PBS at room temperature and subsequently incubated overnight at room
temperature in a DA D2-receptor primary antibody (1:200, mouse monoclonal, Santa
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Cruz Biotechnology, Inc., Santa Cruz, CA, sc-5303). After 24 hours, blots were washed
in PBS-T (0.1% Tween-20) and incubated in secondary antibody (1:5000, donkey antimouse IgG, Jackson Immunoresearch, West Grove, PA, 715-035-151) in 5% non-fat
milk in PBS for 1 hour at room temperature. Blots were then washed in PBS-T and
imaged on a Kodak Image Station 4000 (4 exposures, 15 sec each) using Immobilon
chemiluminescent reagent (Millipore, Bellerica, MA). For loading control, blots were
incubated with anti-actin antibody for 1 hour at room temperature, followed by incubation
with secondary antibody and were re-imaged under the same settings. The samples
were normalized to actin. Integrated density of the bands was analyzed using
AlphaEaseFC (FluorChem 9900) and results were reported as percent of WT.
Determination of Tissue Neurochemical Content by HPLC-EC
Tissues from a separate cohort of mice were used for neurochemical analysis.
Tissues were collected at the Medical University of South Carolina by Heather Boger,
Ph.D. (see Tissue Preparation and Neurochemical Analysis of Tissues (HPLC-EC)).
Mice were anesthetized with isoflurane and euthanized by decapitation. Brains were
quickly removed and placed in an ice-cold mouse brain matrix (ASI instruments, Warren,
MI). Striatal tissue was collected to reflect the general recording sites from the
electrochemical studies. Accordingly, rostral and caudal brain slices were obtained and
tissue punches from the dorsal striata were collected from each slice. Tissue analysis by
HPLC-EC was conducted at the University of Kentucky by Stewart Surgener. Gdnf+/- (n =
7) and WT (n = 8) mice were compared by a two-tailed unpaired t test, keeping rostral
and caudal slices separated.
Locomotor Activity
Locomotor activity measures were performed at the Medical University of South
Carolina by Heather Boger, Ph.D. Locomotor activity (total distance traveled) was
assessed using a Digiscan animal activity monitor system (Omnitech Electronics Model
RXYZCM (8); TAO, Columbus, OH, USA) described previously (Halberda, et al., 1997).
Animals (n = 7) were injected with vehicle (0.9% NaCl, 0.01mL/g body weight, i.p.) and
placed in the activity boxes for 1 hour. After 1 hour, mice were injected with the DAT
inhibitor, nomifensine (7.5 mg/kg, i.p.), and placed into the activity boxes for an
additional 2 hours. Total distance traveled was calculated over 15-minute intervals and
averaged for each genotype.
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Basal locomotor activity data collected following saline injections were analyzed
with a 2 (Genotype) x 4 (Interval) mixed-factor ANOVA with repeated measures on the
interval factor. Because of the genotype difference in basal activity, data collected
following the nomifensine injections were normalized (expressed as percent change)
and analyzed with a 2 (Genotype) x 8 (Interval) ANOVA with repeated measures on the
interval factor.
Data Analysis and Statistics
Outliers > 2 standard deviations from the mean were removed from all data.
Statistical significance was defined as p < 0.05 for all analyses. In reported statistics, n
represents the number of animals unless otherwise indicated.
Results

Nomifensine-Induced Locomotor Activity
Locomotor activity of 12-month-old Gdnf+/- and WT mice was investigated to
determine age-related changes in the movement abilities of the Gdnf+/- mice and the
effects of a catecholamine uptake inhibitor on locomotion in these mice. As seen in
Figure 4.3A, the spontaneous locomotor activity following saline (vehicle) injection was
diminished in the 12-month-old Gdnf+/- mice compared to that of WT mice. A 2
(Genotype) x 4 (Interval) mixed-factor ANOVA, with repeated measures on the interval
factor, provided statistical support for reduced motor activity observed for the Gdnf+/mice [Genotype effect: F1,12= 15.179, p < 0.01].
Following the habituation period, mice were injected with nomifensine – a DAT
inhibitor that causes increased locomotor activity (Altar and Marshall, 1988; Hebert and
Gerhardt, 1998). Because Gdnf+/- mice were less active than WT controls during the
habituation period, data generated following the nomifensine injections were expressed
as change in motor activity relative to the last 15-minute base interval following saline
injection (percent change). Stimulated locomotor activity (Figure 4.3B) showed a greater
nomifensine-induced increase in the 12-month-old Gdnf+/- mice compared to WT mice. A
genotype x interval ANOVA indicated a significant effect of genotype [F7,84 = 3.119, p <
0.01] with Gdnf+/- mice demonstrating greater nomifensine-induced locomotor activity
during the earlier intervals.
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Dopamine Clearance and Uptake Studies
Studies of DA clearance using in vivo electrochemical methods were carried out
in the striata of Gdnf+/- and WT mice to further investigate the functional properties of the
DAT in vivo. These methods have been shown to reliably determine the relative density
of DAT and its kinetic properties in mice and rats (Thomas, et al., 2007). Local
application of DA solution was used to obtain DA signals of equivalent amplitude (771 ±
16, mean ± SEM (nM), n = 107 signals) for DA-uptake analysis. Genotypes were
compared using k-1 (sec-1) (Figure 4.5), the first-order rate constant of the decay of the
DA signals. Gdnf+/- mice and WT mice did not show significant differences in the k-1 in
the dorsal striatum of either recording site: rostral-medial (site 1) [p > 0.05], caudallateral (site 2) [p > 0.05] (Figure 4.5). However, DA uptake kinetics measured by k-1 were
significantly increased in the ventral sub-regions of both recording sites of the Gdnf+/mice versus WT mice [rostral-medial (site 1): t15 = 2.280, *p = 0.0377; caudal-lateral
(site 2): t22 = 2.437, *p = 0.0233] (Figures 4.4; 4.5 A, B). The ventral Str/NAc (recording
site 1) of Gdnf+/- mice showed a 96% increase in mean k-1 compared to WT counterparts
[mean ± SEM (sec-1) WT: 0.0023 ± 0.00045, n = 12; Gdnf+/-: 0.0045 ± 0.0011, n = 5; n
represents the number of signals]. The analogous ventral striatal sub-region of recording
site 2 showed a 100% increase in DA uptake [mean ± SEM (sec-1) WT: 0.0019 ±
0.00016, n = 12 Gdnf+/-: 0.0038 ± 0.00076, n = 12; n represents the number of signals].
A second series of studies compared the amplitudes of the DA signals achieved
per amount of DA solution locally applied to investigate surface expression of the DAT
within striatal sub-regions. We have previously shown that the amplitude of DA signals
per amount of DA applied increases as the surface expression of DAT decreases (Cass
and Gerhardt, 1995; Hebert and Gerhardt, 1999). The resulting amplitude per picomole
varied according to striatal sub-region and genotype (Figure 4.6; 4.7). Increased DA
uptake in the Gdnf+/- mice was evident as the resulting amplitude per picomole of applied
DA solution was reduced in the Gdnf+/- mice. This is evident in both dorsal recording
sub-regions in Gdnf+/- mice (Figure 4.7). There was a 74% decrease in amplitude per
amount of applied DA in dorsal striatum of Gdnf+/- mice compared to WT mice [mean ±
SEM (nM/pmol) (site 1): WT: 167.7 ± 35.6, n = 14; Gdnf+/-: 43.35 ± 11.3, n = 10; (t22 =
2.86, **p = 0.0091); n represents the number of signals] (Figure 4.7 A). Gdnf+/- mice and
WT mice did not show significant differences in the amplitude per picomole in the ventral
Str/NAc (site 1) [p > 0.05] (Figure 4.7 A). Recording site 2 (Figure 4.7 B) showed a 82%
decrease in amplitude per picomole in the dorsal striatum of Gdnf+/- mice [mean ± SEM
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(nM/pmol) (WT: 168.6 ± 29.7, n = 12; Gdnf+/-: 30.23 ± 7.312, n = 10; (t20 = 4.153 ***p =
0.0005); n represents the number of signals] and a 69% decrease in the ventral striatum
[mean ± SEM (nM/pmol) WT: 206.2 ± 45.2, n = 12; Gdnf+/-: 64.39 ± 26.25, n = 10; (t20 =
2.575, *p = 0.0181); n represents the number of signals]. Thus a significant decrease in
the amplitude per picomole of DA that was locally applied and the increase in k-1 indicate
increased clearance of exogenously applied DA in Gdnf+/- mice.
Studies of Dopamine Release
To determine if Gdnf+/- mice exhibited altered DA-release properties in the
striatum, we measured in vivo DA release following local application of potassium
solution (120 mM) (Gerhardt, et al., 1986). This technique has been previously shown to
reliably measure neurotransmitter release from terminals present in the striatum
(Gerhardt, et al., 1986), which primarily reflects DA release (Gerhardt and Hoffman,
2001; Gerhardt, et al., 1984). The change from baseline was calculated following local
application of potassium solution and the average amplitude (μM) was calculated to
compare genotypes within striatal sub-regions. There were no significant changes in
release amplitude at either striatal sub-region in recording site1 (p > 0.05, both subregions) (Figure 4.8 A). In recording site 2 (Figure 4.8 B), both recording regions showed
a significant increase in release amplitude. The Gdnf+/- exhibited a 236% increase in
amplitude versus WT in the dorsal striatum (mean ± SEM (μM) WT: 2.90 ± 0.67, n = 12;
Gdnf+/-: 9.75 ± 1.75 n = 10; t20 = 3.908, ***p = 0.0009; n represents the number of
signals). Similarly, in the ventral striatum there was a significant increase in amplitude
(90%) in the Gdnf+/- mice versus WT mice [mean ± SEM (μM) WT: 0.74 ± 0.30, n = 9;
Gdnf+/-: 7.6 ± 1.79, n = 8; t15= 4.032, **p = 0.001; n represents the number of signals].
Striatal Dopamine D2-receptor mRNA and Protein Expression
In a separate cohort of mice, striatal DA D2-receptor mRNA and protein
expression was assessed in WT and Gdnf+/- mice to determine a potential connection
between altered D2-receptor expression and DAT activity (Figure 4.9 A). Using in situ
hybridization histochemistry, striatal DA D2-receptor mRNA expression was determined.
Gdnf+/- mice had significantly higher DA D2-receptor mRNA in the dorsal striatum than
WT mice (Figure 4.9 A, B) [t8 = 3.387, **p = 0.0095, mean ± SEM (percent of WT),
Gdnf+/-: 217.0 ± 29.8 n = 4; WT: 100 ± 20.2, n = 6]. In addition to an increase in striatal
DA D2-receptor mRNA, D2-receptor protein in the striatum was also increased in 1268

month-old Gdnf+/- mice versus WT mice (Figure 4.9 B, t6= 3.192, *p = 0.0188, mean ±
SEM (percent of WT), Gdnf+/-: 130.3 ± 8.53 n = 4; WT: 100 ± 4.21, n = 4).
Striatal Tissue Measures of Dopamine and Metabolites and Serotonin and
Metabolites by HPLC-EC
To determine if there were concurrent alterations in DA-synthesis or -metabolism,
analyses of DA and primary metabolites (DOPAC, HVA) were performed on tissue
samples harvested from rostral (site 1: anterior-posterior +1.0) and caudal (site 2:
anterior-posterior +0.1) sections of the mouse striatum (n = 7-8 per genotype; Table 4.1).
The Gdnf+/- mice had lower striatal tissue levels of DA versus WT mice in both brain
sections [site 1: anterior-posterior +1.0, t13 = 3.541, **p = 0.0036; site 2: anteriorposterior +0.1, t13 = 2.281, *p = 0.0401]. The genotypes did not differ in tissue content of
DOPAC or HVA at either set of coordinates. Dopamine turnover was significantly
elevated at both recording sites in Gdnf+/- mice as indicated by the increase in ratios of
HVA:DA [site 1: anterior-posterior +1.0, t13 = 3.631, *p = 0.0268; site 2: anterior-posterior
+0.1, t13 = 3.812, **p = 0.0022] and (DOPAC + HVA):DA [site 1: anterior-posterior +1.0,
t13=2.496, *p = 0.0268; site 2: anterior-posterior +0.1, t13 = 4.092, **p = 0.0013]. In
addition, Gdnf+/- mice differed in the DOPAC:DA ratio compared to WT mice in the
caudal striatum [site 2, anterior-posterior +0.1, t13 = 2.264, *p = 0.0413]. Thus, Gdnf+/mice demonstrated decreased DA tissue storage, which likely contributed to decreases
in DA turnover ratios.
Whole tissue levels of 5-HT and the primary metabolite 5-hydroxyindoleacetic
acid (5-HIAA) were also investigated by HPLC-EC from striatal tissues (Table 4.1). The
genotypes did not differ in tissue levels of 5-HT or 5-HIAA at either recording site (p >
0.05). However, the ratio of 5-HIAA:5-HT in the caudal region of the striatum (site 2) was
significantly greater in Gdnf+/- mice compared to WT mice [t13 = 2.388, *p = 0.03].
Discussion
These studies reveal dynamic alterations in DA neurotransmission in the striatum
of middle-aged Gdnf+/- mice. Locomotor experiments indicated lower spontaneous
activity in the 12-month-old Gdnf+/- mice than in WT mice, confirming previous reports
(Boger, et al., 2006). By contrast, nomifensine produced greater relative increases in
locomotor activity of the Gdnf+/- mice, suggesting alterations in DAT function and/or
postsynaptic DA signaling. Behavioral data also demonstrated that mice with a partial
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Gdnf deletion are capable of achieving increased locomotor activity comparable to and
surpassing WT activity. Electrochemical recordings were conducted to determine if there
were presynaptic functional changes in DA uptake mechanisms or the magnitude of
evoked DA release. In vivo electrochemical recordings of DA uptake indicated a higher
rate, k-1, of DA uptake in the ventral striatal sub-regions of Gdnf+/- mice compared to WT
mice. In addition, Gdnf+/- mice showed significant decreases in the amplitude per
picomole of DA applied in multiple striatal sub-regions compared to WT mice. Thus, the
chronoamperometric studies confirm that Gdnf+/- mice have increased high-affinity DA
uptake in vivo, consistent with an increase in the relative Bmax. Additionally, DA release
was altered in dorsal and ventral striatal recording sub-regions. Assessment of striatal
tissue levels of DA and DA metabolites indicated lower DA levels in the Gdnf+/- mice,
which is consistent with decreased spontaneous locomotor activity and fewer THpositive neurons in the SNc (Boger, et al., 2006). Taken together, these data
demonstrate in vivo functional changes in middle-aged Gdnf+/- mice that support a role
for GDNF in age-related DA-neuron dysfunction (Yurek and Fletcher-Turner, 2001;
Yurek, et al., 1998).
Middle-aged Gdnf+/- Mice Show Enhanced Behavioral Sensitivity to DAT
Inhibition by Nomifensine
The diminished spontaneous activity observed for the 12-month-old Gdnf+/- mice
corroborates results of a previous study that established a locomotor activity reduction
and, furthermore, a positive correlation between reduced motor activity and fewer THpositive neurons in the SNc (Boger, et al., 2006). Consistent with previous reports, DAT
inhibition by nomifensine increased spontaneous motor activity in both genotypes (Altar
and Marshall, 1988; Marshall and Altar, 1986). Although the DAT inhibitor elevated
activity in both genotypes, the response was increased in the Gdnf+/- mice. Importantly,
the increased stimulated locomotor activity in Gdnf+/- mice suggests that Gdnf+/- mice are
capable of increased activity i.e. lower motor function that may be affected by GDNF
depletion is intact (Oppenheim, et al., 2000). Interestingly, the enhanced response to
nomifensine seen for middle-aged Gdnf+/- mice in the current study was not observed in
other experiments using younger (3-month-old) Gdnf+/- mice (Boger, et al., 2007).
Consideration of results in these and previous experiments suggests that GDNF
depletion and the aging process interact and result in progressive alteration of
nigrostriatal function. This interpretation is consistent with the increase in DAT activity
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observed in aging (from 3- to 12-month-old) Gdnf+/- mice and not WT counterparts
(Boger, et al., 2007). Diminished DA uptake is evident in aged rats (Friedemann, 1992;
Hebert and Gerhardt, 1999) and is accompanied by an attenuated effect of nomifensine
on locomotor behavior (Stanford, et al., 2002) and reductions in DAT density (Hebert, et
al., 1999). Considering these previous studies in our model, the increased sensitivity to
nomifensine suggests an increase in high-affinity DA uptake by the DAT in the Gdnf+/mice, which was confirmed by the in vivo chronoamperometric studies discussed below.
Previous work, showing comparatively weak inhibition of the 5-HT transporter
(SERT) by nomifensine (Tuomisto, 1977) and a lack of effect of SERT inhibition on
locomotor activity (Hebert and Gerhardt, 1998), support a minor, if any, contribution from
serotonergic systems in these studies. Further evidence is provided by striatal tissue
analysis for 5-HT and 5-HIAA (see Middle-aged Gdnf+/- Mice Demonstrate Decreased
DA Synthesis and increased DA Turnover without Regional Alterations in 5-HT).
Regarding potential involvement of serotonergic systems in the clearance studies
(discussed below), prior work shows the clearance of locally applied DA in the striatum is
unchanged following selective inhibition of SERT (Cass and Gerhardt, 1995). Thus, the
described alterations are most likely due to changes in DAT function.
Middle-aged Gdnf+/- Mice Show Increased Dopamine Uptake In Vivo
Aged rats are reported to have changes in DA-uptake and -release kinetics in the
dorsal striatum that are postulated to contribute to age-related motor deficits (Hebert and
Gerhardt, 1998). In the current study the increase in the decay constant, k-1, in the
ventral striatum (caudal-lateral, site 2) and ventral Str/NAc (rostral-medial, site 1)
indicates a more selective effect on mesoaccumbens (A10) DA projections versus
nigrostriatal (A9) DA projections, which are the primary source of DA in the dorsal
striatum (Bentivoglio and Morelli, 2005). We would expect limbic behaviors, particularly
those influenced by DAT modulation, to be altered in Gdnf+/- mice. Indeed, altered
response to reward has been demonstrated in Gdnf+/- mice (Airavaara, et al., 2007; Yan,
et al., 2007). Increased DA clearance in mesolimbic projections of Gdnf+/- mice is also
interesting in light of prior findings that GDNF supplementation attenuates behavioral
adaptations following administration of addictive drugs (Ghitza, et al., 2009; Messer, et
al., 2000). Although reward and reinforcing behaviors are traditionally attributed to
mesolimbic DA projections (Di Chiara and Imperato, 1988), mesolimbic DA
neurotransmission in the NAc and surrounding ventral striatum may also influence motor
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activity (Koob, et al., 1981; Pijnenburg, et al., 1976) – a function historically associated
with nigrostriatal DA projections (Kirik, et al., 1998). With consideration of placement
variation between animals, striatal heterogeneity (Glynn and Yamamoto, 1989) and the
diffuse anatomical boundaries of mesolimbic and nigrostriatal projections, it is unlikely
that either of the ventral sub-regions studied reflect mesoaccumbens projections
exclusively (Beckstead, et al., 1979; Fallon and Moore, 1978a). We believe DA
innervation from the SNc likely contributes to the uptake changes seen in the ventral
sub-regions. Indeed, analysis of the amplitude per picomole of DA solution applied
indicates uptake changes in both dorsal sub-regions (sites 1 and 2) and the ventral
striatum (site 2). Previous work has shown that the positive relationship between DAsignal amplitude from increasing amounts of locally applied DA solution is linear (Cass
and Gerhardt, 1995; Hebert and Gerhardt, 1999). The relationship between the amount
of locally applied DA and the resulting amplitude is associated with DAT function and
was previously shown to reflect an in vivo Bmax, which allows for comparison of the
relative number of functional DA-uptake sites (Cass and Gerhardt, 1995; Cass, et al.,
1993; Hoffman and Gerhardt, 1998).
The increased striatal DA uptake in Gdnf+/- mice provides in vivo confirmation of
earlier in vitro work indicating increased DAT activity in striatal synaptosomes from
Gdnf+/- mice (~30% increase in DA uptake compared to age-matched WT mice) (Boger,
et al., 2007). Because in vitro experiments indicated increased DAT activity in tissue
from Gdnf+/- mice without changes in DAT protein expression, upregulation of DAT
expression is unlikely to underlie the current findings. An increase in Bmax due to
increased surface expression of DAT on the plasma membrane of DA terminals and
varicosities in the striatum, however, supports the enhanced sensitivity to DAT inhibition
by nomifensine seen in the locomotor data as well as chronoamperometric studies.
Indeed, increased surface expression of the DAT in Gdnf+/- mice would explain the
discrepancy between unchanged DAT protein levels and increased DAT activity in vitro
(Boger, et al., 2007). Future studies should be conducted to determine the surface
expression of the DAT in Gdnf+/-. A possible underlying mechanism regarding DAT
surface expression is decreased internalization of the transporter via attenuated activity
of protein kinase C (PKC), which has been implicated in molecular control of endocytosis
of the DAT (Sorkina, et al., 2005). This possibility requires further investigation.
Altered DA uptake is common to aging studies in rats (Hebert and Gerhardt,
1998; Yurek, et al., 1998) and the Gdnf+/- mice. The former involves diminished uptake
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while the model examined here demonstrates increased DA uptake with an enhanced
response to nomifensine rather than the attenuated response observed in prior studies
in aged rats (Hebert and Gerhardt, 1998). Changes in DAT activity have been postulated
to function in maintaining DA signaling in lesioned (Hoffman and Gerhardt, 1998; van
Horne, et al., 1992) and aged (Hebert and Gerhardt, 1999; Hebert, et al., 1999) animal
models of DA dysfunction – modulating signal duration by increasing the amount of DA
and/or time synaptic DA is available. We postulate that increased DAT activity observed
for Gdnf+/- mice is accompanied by relative decreases in tonic levels of synaptic and
extracellular DA resulting in decreased postsynaptic DA-receptor activation.
Middle-aged Gdnf+/- Mice Show Increased Dopamine Release In Vivo
The phasic component of DA release is investigated in the electrochemical
potassium-evoked release studies. To our knowledge DA release has not been
investigated in middle-aged Gdnf+/- mice. Release dynamics are of interest in the context
of DA neurotransmission, which has been associated with regulation of GDNF
expression (Ohta, et al., 2003). Compensatory mechanisms involving DA release or
postsynaptic aspects of DA signaling in Gdnf+/- mice may develop to counter GDNF
protein reductions. More widely studied than GDNF depletion, GDNF supplementation
and DA release have been investigated in numerous animal models (Cass, et al., 2000;
Grondin, et al., 2003) including the normal (young) (Hebert, et al., 1996) and aged rat
(Hebert and Gerhardt, 1997). When delivered to the primary cell bodies of the SNc,
GDNF supplementation caused an increase in evoked DA release in the rat striatum
(Hebert and Gerhardt, 1997; Hebert, et al., 1996). We would predict GNDF depletion to
have a diminishing effect on DA release, which is not the case in this depletion model
(Gdnf+/-) with significant increases in release. Generally, in GNDF-supplementation
studies GDNF is administered locally (i.e. to the primary cell bodies of the SNc) in the
adult rat. The experimental circumstances of previous experiments make direct
comparison to Gdnf+/- mice problematic, if not inappropriate, because global brain GDNF
depletion (Boger, et al., 2006; Gerlai, et al., 2001) and potential impact on
developmental processes (Granholm, et al., 2000; Stromberg, et al., 1993) are not
comparable to GDNF treatment to a single brain area in the adult animal.
In the aged rodent, motor deficits have been attributed to presynaptic dysfunction
including diminished DA-release and -clearance (Hebert and Gerhardt, 1998; Hebert and
Gerhardt, 1999; Yurek, et al., 1998). It has been postulated that DA-release and -uptake
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dynamics interact to modulate DA signaling i.e. uptake is reduced in order to prolong
DA-receptor activation during diminished release. In Gdnf+/- mice, the increased DAT
activity may exist to meet the demands of increased phasic release of DA. In this case,
the exclusivity of increased DA release to recording site 2 is surprising because uptake
is altered in both recording sites. Indeed, the interaction of uptake and release
phenomena in Gdnf+/- mice is highly speculative and it is unclear if a cause-and-effect
relationship exists or to which the release and uptake phenomena may be attributed.
Characterization of other (younger) age groups is necessary to make more definitive
conclusions about the cause-and-effect relationship between DA-release and -uptake in
this model.
Middle-aged Gdnf+/- Mice Show Increased Dopamine D2 Receptor mRNA and
Protein
Decreased DA-receptor activation would support diminished spontaneous motor
activity in Gdnf+/- mice reported in this study and previous work (Boger, et al., 2006).
However, here we observed an increase in DA D2-receptor mRNA and protein in the
striatum of Gdnf+/- mice (Boger, et al., 2004). We hypothesize that increased DAT activity
may cause reduced tonic levels of synaptic DA in Gdnf+/- mice and a compensatory
increase in DA D2-receptor expression. Thus, the stimulated motor response to
nomifensine is exacerbated in the Gdnf+/- mice due to: 1) enhanced sensitivity to
nomifensine and 2) increased D2-receptor activation. Because these assays do not
examine surface expression/functional DA-receptors, the discussion should be
considered with this caveat. In addition, definitive conclusions about the involvement of
the D2 autoreceptor and potential role in DA-uptake properties cannot be made from the
protein and mRNA assays, which reflect mainly postsynaptic D2 receptors (Levey, et al.,
1993). The contribution of D2 autoreceptors is possible but requires more direct
investigation. Inhibition of DA D2-receptors has been shown to produce a modest (~40%)
decrease in DA clearance (amp/pmol) (Cass and Gerhardt, 1994) compared to the
~80% decrease in amp/pmol in the middle-aged Gdnf+/- mice. Thus, it is unlikely that
changes in D2-autoreceptor function, alone, cause the observed DA-uptake alterations.
Additionally, PKC mediated regulation of DAT membrane trafficking, a potential
mechanism proposed previously, has been shown to function independently of DA D2receptors (Furman, et al., 2009). Although protein and mRNA levels are significantly
increased, profound receptor changes are also unlikely considering the modest decline
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(~25%) in tissue DA levels, which do not fulfill required deficits (>90%) for receptorhypersensitivity phenomena (Hefti, et al., 1980). Future studies should be conducted to
further investigate striatal D2-receptor surface expression and activation as well as tonic
extracellular DA levels in the Gdnf+/- mice.
Middle-aged Gdnf+/- Mice Demonstrate Decreased DA Synthesis and
Increased DA Turnover without Regional Alterations in 5-HT
Analyses of DA and metabolites were conducted to determine if synthesis and
metabolism of DA were altered in the striatum of Gdnf+/- mice. Tissues from rostral and
caudal striatal sections (recording sites 1 and 2, respectively) showed decreases in DA
tissue levels (average ~25%) that indicate decreased DA synthesis. Decreased DA
synthesis is expected because of the reduced number of TH-positive cell bodies in the
SN (Boger, et al., 2006). Although there is evidence for decreased striatal TH-staining
density (Boger, et al., 2007), it is also possible that the relative activity of TH is reduced
due to dephosphorylation – an aspect of TH activity enhanced by GDNF
supplementation (Salvatore, et al., 2009; Salvatore, et al., 2004). Given the nature of the
global brain depletion of GDNF protein in Gdnf+/- mice, both nigral and striatal TH
phosphorylation may be affected. The increased ratio of metabolites to DA indicate
increased DA metabolism. This is likely due to the decreased levels of DA because DA
metabolites, DOPAC and HVA, were not significantly different compared to WT mice.
HPLC-EC quantification of 5-HT and its metabolites were carried out to examine
serotonergic changes in Gdnf+/- mice. There were no changes in whole tissue 5-HT or
metabolite (5-HIAA) levels at either recording site, which supports a minor contribution of
serotonergic systems in the described studies. Although the ratio of 5-HIAA:5-HT in the
caudal region of the striatum (site 2) was increased in Gdnf+/- mice versus WT mice [p =
0.03], it is unlikely that serotonergic systems influence electrochemical results given the
comparatively low density of 5-HT innervation compared to DA in the striatum (Schenk,
et al., 1983) and lack of effect of SERT inhibition on DA uptake parameters (Hoffman
and Gerhardt, 1998).

Implications and Explanations of Increased Dopamine Transporter
Function
Boger et al., (2007) showed increased susceptibility to methamphetamineinduced toxicity in Gdnf+/- mice and attributed the susceptibility to increased DAT activity.
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Although the mechanisms of increased DAT activity have not been determined, we
would predict increased DAT activity and/or surface expression of the DAT to also cause
increased susceptibility to other DA-neuron toxins like MPTP and 6-OHDA, which use
the DAT for cellular entry and associated toxicity (Gainetdinov, et al., 1997; Storch, et
al., 2004).
In 6-OHDA lesioned rats, high-affinity DA uptake by the DAT is diminished due to
a profound loss of striatal DA terminals (Hoffman and Gerhardt, 1998). However,
previous work showed decreases in TH-positive fiber density and TH-positive neurons in
the SN of Gdnf+/- mice (Boger, et al., 2006), making increased functional DA terminals in
Gdnf+/- mice an unlikely cause of increased DAT activity. In addition, the decrease in
striatal DA content (see Middle-aged Gdnf+/- Mice Demonstrate Decreased DA
Synthesis and increased DA Turnover without Regional Alterations in 5-HT) supports
that an increase in functional DA terminals is unlikely.
Altogether, these data support increased DA-clearance capacity in middle-aged
Gdnf

+/-

mice, which may be due to increased DAT activity and/or density of DAT

membrane expression as seen in the aged rat (Hebert, et al., 1999) and human brain
(Volkow, et al., 1994). It is unclear if the GDNF depletion in this model varies within the
striatum because previous characterization studies have focused on the entire striatum,
excluding the NAc (Boger, et al., 2006). A differential effect of GDNF on DA terminals in
the striatal sub-regions due to differential spatial expression of GDNF in this model could
contribute to the current findings. These results require further investigation to determine
the definitive mechanism(s) that may underlie the apparent uptake changes.

Conclusions
Motor and pathological manifestations associated with the Gdnf+/- mice become
apparent later in life and progress gradually (Boger, et al., 2006). This progressive time
course contrasts with other DA-lesion models where the onset of neurodegeneration is
comparatively rapid and severe (Ichitani, et al., 1994; Kirik, et al., 1998; Lee, et al., 1996;
Sauer and Oertel, 1994) and deficits may recover with time (Yuan, et al., 2005). The
Gdnf+/- mouse is a novel model of DA dysfunction that demonstrates some of the subtle
aspects of human DA-neuron dysfunction seen in aging. The regulation of GDNF has yet
to be clearly defined for aging and DA-neuron dysfunction in general. There are
contradictory results regarding the regulation of GDNF in DA-neuron dysfunction and in
age-associated movement disorders like PD. It has been suggested that GDNF isoforms
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may be differentially expressed in PD with an increase in isoform I (Backman, et al.,
2006). By contrast, decreases in GDNF levels have been reported in the SN of PD
patients (Jenner and Olanow, 1998). In animal models of DA dysfunction, both increased
(Nakajima, et al., 2001) and unchanged levels of striatal GDNF (Smith, et al., 2003) have
been reported following 6-OHDA administration. Our studies indicate changes in DAneurochemistry, -uptake and -release accompanied by behavioral deficits using a model
of chronic and partial genetic reductions of GDNF that appears to manifest age-related
changes.
Taken together, these studies support a unique role for GDNF in the
development, function and maintenance of DA neurons. Further studies are necessary
to determine the specific mechanisms that underlie the apparent neurochemical and
kinetic changes in DA regulation as well as the widespread implications of these
changes.
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Chapter Four: Figures

Figure 4.1 Representation of Microelectrode Placement in the Mouse Brain
The diagrams show the approximate location of the microelectrode at (A) site 1 and (B)
site 2 (coordinates relative to bregma (mm)). Bilateral recordings were conducted for
DA-uptake and -release studies. The microelectrode was lowered using increments of
400 μm through the dorsal-ventral axis of the striatum.
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Figure 4.2 Analysis parameters for In Vivo Electrochemical Dopamine Signals
The current measured by the microelectrode was converted to concentration (shown) by
dividing the measured current (nA) by the calibration slope (nA/μM) determined for each
microelectrode prior to use (inset: axes units). Following local application of DA solution
(100 μM, indicated by arrow) in the uptake studies, the amplitude was calculated as
change from a stable baseline. The first order exponential decay constant, (1) k -1 (sec-1),
was calculated from the decay portion of the DA signal fitted to the slope of the linear
regression of the natural log transformation of the data. By dividing the resulting DA
signal amplitude by the amount (picomole) of DA solution applied, the (2) amplitude per
picomole was calculated. For DA-release studies, DA signals resulting from local
application of high-potassium solution (120 mM, arrow) were analyzed by calculating the
(3) maximum amplitude (nM) as the concentration change from baseline.
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Figure 4.3. Spontaneous and Nomifensine-induced Locomotor Activity in 12-month-old
Gdnf+/- and WT Mice
Saline-injected Gdnf+/- mice showed a decrease in total distance traveled compared to
WT mice (A) [F

1,12

= 15.179, **p < 0.01]. Gdnf+/- mice showed greater nomifensine-

induced locomotor activity compared to nomifensine-treated WT mice (B) [F7,84 = 3.119,
**p < 0.01]. Data are shown as mean ± SEM and were analyzed by a 2 (Genotype) x 4
(Interval) mixed-factor ANOVA with repeated measures on the interval factor (A) and 2
(Genotype) x 8 (Interval) mixed-factor repeated-measures ANOVA.
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Figure 4.4 Representative Trace of Dopamine Uptake in Gdnf+/- Mice
A DA solution (100 μM) was locally applied (arrow) in the mouse striatum to obtain DA
signals of equivalent amplitude (inset: axes units). For amplitude-matched DA signals,
uptake (quantified as k-1) was increased in Gdnf+/- mice – demonstrated by the increase
in slope of the decay portion of the signal.
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Figure 4.5. Average k-1 (sec-1) from Dorsal and Ventral Striatal Recording Sub-regions of
Gdnf+/- and WT Mice
Local application of DA solution was used to obtain DA signals within an amplitude
range, 500-1000 nM, for uptake analysis. The k-1 was analyzed to compare Gdnf+/- and
WT mice. The k-1 was not significantly changed between genotypes in the dorsal striatum
of the rostral-medial recording site 1 or caudal-lateral recording site 2. The k-1 did show
genotype differences exclusive to the ventral Str/NAc of the rostral-medial recording site
1 [*p = 0.0377] (A) and ventral striatum of the caudal-lateral recording site 2 [*p =
0.0233] (B). There were significant increases in DA uptake in Gdnf+/- mice. Data shown
as mean ± SEM and were analyzed by a two-tailed unpaired t test comparing genotypes.
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Figure 4.6 Representative Trace of Dopamine Signal Amplitude (for equivalent amount
of DA applied) in Gdnf+/- Mice
A DA solution (100 μM) was locally applied (arrow) in the mouse striatum. The resulting
amplitude (nM) was divided by the amount of DA applied (picomole) to calculate the
amplitude per picomole (inset: axes units). The amplitude for an equivalent amount of
DA applied was signficantly decreased in Gdnf+/- mice.
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Figure 4.7 Amplitude per Amount of Locally Applied Dopamine in Gdnf+/- Mice
The volume of solution was controlled in order to obtain signals of amplitudes ranging
from 500-1000 nM for uptake analysis. The resulting amplitude per picomole was
analyzed to compare Gdnf+/- and WT mice. All striatal sub-regions showed a decrease in
the average amplitude per picomole applied in the Gdnf+/- mice compared to WT mice.
The amplitude per picomole was not significantly different between genotypes in the
ventral Str/NAc of the rostral-medial recording site 1 (A). The dorsal striatum, however,
showed a significant difference between genotypes [**p = 0.0091]. Both recording subregions of recording site 2 (B) showed a significant difference in amplitude per picomole
[***p = 0.0005] (dorsal striatum) and [*p = 0.0181] (ventral striatum). Data are shown as
mean ± SEM and were analyzed by a two-tailed unpaired t test comparing genotypes.
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Figure 4.8 Average Amplitude of Evoked-Dopamine Signals from Gdnf+/- Mice
A potassium chloride solution (120 mM) was applied locally (75-150 nL) in order to
measure DA release in the striatum of Gdnf+/- mice. The resulting amplitude from striatal
sub-regions was averaged and analyzed to compare genotypes. Neither the dorsal nor
ventral striatum/NAc showed significant differences in DA release in the rostral-medial
recording site 1 (A). Both striatal sub-regions showed significant differences in DA
release in the caudal-lateral recording site 2 (B). Gdnf+/- mice demonstrated increased
DA release compared to WT mice in the dorsal [***p = 0.0009] and ventral striatum [**p
= 0.0011]. Data are shown as mean ± SEM and were analyzed by a two-tailed unpaired t
test comparing genotypes.
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Figure 4.9. Striatal Dopamine D2-Receptor mRNA and Protein Expression in Gdnf+/- Mice
In situ hybridization immunohistochemical detection indicated an increase in DA D2receptor mRNA in the dorsal striatum of Gdnf+/- mice compared to WT (A) [*p = 0.0095].
Protein levels of the DA D2-receptor (B) were also significantly increased in the dorsal
striatum of Gdnf+/- mice compared to WT mice [*p = 0.0188]. Data are shown as mean ±
SEM and were analyzed by a two-tailed unpaired t test comparing genotypes
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Table 4.1 Tissue Neurochemical Content in 12-month-old Gdnf+/- Mice

Data shown as mean ± SEM (ng/g wet weight of tissue). Analyzed by a two-tailed unpaired t test comparing genotypes.
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Chapter Five: GDNF Replacement in Gdnf+/- Transgenic Mice
Introduction
The use of trophic factor supplementation, particularly in the context of PD, has
been widely investigated with promising findings of enhanced neuron function and
behavioral measures (Peterson and Nutt, 2008). In particular, GDNF has shown
restorative effects in numerous animal models exhibiting DA-neuron dysfunction
including the aged and 6-OHDA lesioned rat (Hebert and Gerhardt, 1997; Hoffer, et al.,
1994) and the aged and MPTP-lesioned non-human primate (Grondin, et al., 2003;
Grondin, et al., 2002). GDNF has also demonstrated protective effects from 6-OHDAand MPTP-induced cytotoxicity in rodents (Kearns, et al., 1997; Tomac, et al., 1995).
GDNF is a target derived neurotrophic factor that is expressed at highest levels in the
developing striatum with declining expression levels in adulthood (Stromberg, et al.,
1993). In light of the restorative- and protective-effects of GDNF on DA neurons and the
prominent role of GDNF in development (Granholm, et al., 2000), the effects of a chronic
GDNF depletion have been investigated using GDNF heterozygous mice (Gdnf+/-), which
have decreased GDNF protein expression in the brain (Boger, et al., 2006; Pichel, et al.,
1996).
Gdnf+/- heterozygous mice display a unique aging phenotype with locomotor
deficiencies, decreases in TH-positive staining in the SN and functional changes in DArelease and -uptake properties in the striatum (Boger, et al., 2006; Littrell, et al., 2010)
(see also Chapter Four: Dynamic Changes in Nigrostriatal Dopamine-Neuron Function in
Gdnf+/- Mice – A Novel Model of Nigrostriatal Dysfunction). The decline in motor activity
is of interest due to the modest reduction (~25%) in DA levels seen in Gdnf+/- mice
(Littrell, et al., 2010) – far below the typical threshold seen upon emergence of motor
deficits in PD (Bernheimer, et al., 1973) and animal models of PD (Hudson, et al., 1993;
Kirik, et al., 1998). Functional and behavioral abnormalities in the absence of profound
DA-neuron reductions, seen in middle-aged Gdnf+/- mice, are also demonstrated with
aging in animal models (Grondin, et al., 2003; Hebert and Gerhardt, 1998; Hebert and
Gerhardt, 1999) and aging in humans (Bennett, et al., 1996).
Because of indications for enhanced DA-neuron function and parallel behavioral
improvements after GDNF treatment in aged animals (Grondin, et al., 2003; Hebert and
Gerhardt, 1997), neurochemical function and behavioral measures were investigated
after GDNF treatment in Gdnf+/- mice. GDNF replacement in a chronic GDNF depletion
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model was investigated to test the hypothesis that age-related DA-neuron deficiencies
and related behavioral impairments are reduced by GDNF treatment in middle-aged (12month-old) Gdnf+/- mice. The following questions were investigated: 1) Does GDNF
treatment affect spontaneous or stimulated locomotor activity? 2) Does GDNF treatment
restore the number of DA neurons/DA-neuron fiber density in the SN? 3) Are there
changes in DA-neuron functional measures after GDNF treatment?
Materials and Methods

Reagents
Recombinant methionyl human GDNF (Amgen, Thousand Oaks, CA, USA),
expressed in Escherichia coli as previously described (Lin, et al., 1993), was used.
Delivery of GDNF
GDNF was dissolved (5 μg/μL) in sterile (0.22 μm filtered) citrate buffer (10 mM
sodium citrate, 150 mM NaCl, pH = 5) as described previously (Hebert, et al., 1996).
See Intracranial Drug Delivery - Survival Surgical Procedures for general infusion
procedures. Gdnf-+/- mice (12-month-old) (n = 13), age-matched WT littermate mice (n =
9) and age-matched (non-transgenic/non-littermate) C57/Bl6 mice (n = 7) were treated
with 10 μg of GDNF (bilaterally) or equivalent volume of citrate buffer (vehicle) to the
striata. The dose was selected based on studies in rodents (Hebert, et al., 1996;
Hudson, et al., 1995). Stereotaxic coordinates were (from bregma (mm) (bilaterally)):
anterior-posterior: +1.0, medial-lateral: +/-1.5, dorsal-ventral: -3.0 (Franklin and Paxinos,
2001; Kirik, et al., 2004). GDNF and vehicle treatments were administered bilaterally at a
rate of 0.2 μL/min for 10 minutes. There was significant attrition due to anesthetic
intolerance prior to and during electrochemical recording in all treatment groups and
genotypes. Thus, some of the treated animals were not viable for use in electrochemical
recordings and brain tissue neurochemical analysis. The resulting sample size is
indicated in statistics sections.

Locomotor Activity
Animals were monitored for locomotor activity using methods modified from
those described previously (see Locomotor Activity). Animals were tested for
spontaneous motor activity prior to treatment with vehicle or GDNF and randomly
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assigned to treatment groups. Pre-treatment locomotor activity was analyzed using a
two-tailed unpaired t test. Spontaneous motor activity was determined weekly (1-4
weeks after treatment) using the total distance traveled over the 1-hour period. At the 4week time point, animals were injected with saline (0.9% NaCl, 0.01mL/g body weight,
i.p.) before measuring spontaneous locomotor activity. Spontaneous locomotor activity
was analyzed using a 2 (genotype) x 2 (treatment) x 4 (intervals) mixed-factor ANOVA
with repeated measures on the interval factor.
Stimulated motor activity was measured (4 weeks after treatment only) using the
DAT inhibitor nomifensine (7.5 mg/kg i.p.). Stimulated motor activity was analyzed using
a genotype x treatment 1 (GDNF/vehicle) x treatment 2 (nomifensine/saline) three-way
ANOVA.
Electrochemical Recordings
-+/-

Gdnf

(12-month-old) and age-matched WT littermate mice were prepared for

electrochemical recordings as described (see In Vivo Electrochemical Recording and
Microdialysis – Non-Survival Surgical Procedures). Experiments were designed to
reproduce previous recordings methods using stereotaxic coordinates described (Figure
4.1) (see also Electrochemical Recordings). To determine DA-release characteristics
after GDNF treatment, evoked DA release was investigated (bilaterally) using local
application of a high-potassium solution. Electrodes used in these studies were selective
for DA (versus ascorbate (≥ 70:1)), exhibited linear responses to DA (R2 ≥ 0.99) and had
average detection limits (LOD) of 26.4 ± 5.53 (mean ± SEM (nM), n = 31 (electrodes)).
Signals used for analysis exhibited reduction:oxidation ratios of 0.75 ± 0.014, mean ±
SEM, n = 172 (signals) – consistent with the electrochemical profile for DA (Gerhardt
and Hoffman, 2001; Gerhardt, et al., 1986).
Data were analyzed using the two most dorsal and two most ventral recording
depths from each recording site to determine release characteristics (amplitude change
from baseline (Δ, μM)) for striatal sub-regions (Figure 4.1, see also Electrochemical
Recordings, Analysis of Electrochemical Recordings).

Determination of Tissue Neurochemical Content by HPLC-EC
Tissues were obtained from the striata using modifications from methods
described previously (see Tissue Preparation and Neurochemical Analysis of Tissues
(HPLC-EC)). Mice were decapitated while under deep urethane anesthesia. Rostral and
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caudal brain slices were chosen to reflect the general recording sites. Brain slices were
further sectioned into dorsal and ventral sections based on the heterogeneous functional
characteristics (see Dopamine Clearance and Uptake Studies). Analyses of tissue
neurochemical content were performed by Wayne Cass, Ph.D.

Substantia Nigra Immunohistochemistry (TH-ir and GDNF-ir)
Immunohistochemistry was performed at the Medical University of South
Carolina by Heather Boger, Ph.D as described previously (Boger, et al., 2006). After
electrochemical recordings, mice were euthanized while under deep anesthesia and
brains were dissected. Brains were stored in 4% paraformaldehyde at 4° C for 24 hours
and transferred to 30% sucrose until cryo-sectioning (45 μm; Microm, Zeiss,
Thornwood, NY). A polyclonal TH antibody (TH; 1:5000; Pel-Freeze Inc., Roger, AZ) and
a polyclonal GDNF antibody (1:100; Santa Cruz Biotechnology, Inc.) were used for freefloating immunohistochemistry on the SN – using every 3rd section for TH and every 6th
section for GDNF. Peroxidase activity was quenched by treating sections with H2O2,
methanol and 0.01 M tris buffered saline (TBS) (ratio of 1:2:7; pH = 7.6) for 15 minutes
followed by permeabilization in TBS with 0.25% TritonX-100 (TBST) and treatment with
sodium-m-peroxidate (0.1M, in TBS; 20 minutes). Non-specific binding was controlled by
incubation at room temperature in 10% normal goat serum for 30 minutes. Sections
were incubated with the primary antibody for 24 hours (TBST with 3% NGS), washed
with TBST and then incubated with the secondary antibody (1:200, Vector Labs,
Burlingame, CA) and avidin-biotin complex (ABC kit, Vector Labs). The reaction was
developed using 3′3′-diaminobenzidine (0.05% of 3% H2O2) using 2.5% nickel
ammonium sulfate to enhance the reaction. Sections were mounted on glass slides and
cover-slipped.
Unbiased Stereological Cell Counts
Stereological cell counts were performed at the Medical University of South
Carolina by Heather Boger, Ph.D. Quantitative estimates of total numbers of THimmunoreactive (TH-ir) neurons in SN were determined by unbiased stereological cell
counts from serial sections through the midbrain. Methods described previously were
followed (Gundersen, et al., 1988; West, 1993). The optical fractionator system used in
the present study was Stereo Investigator stereological software (MicroBrightfield,
Colchester, VT) coupled to a Prior H128 computer-controlled x-y-z motorized stage.
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Outline contours were drawn at low magnification (10x) and the outlined region
measured with a systematic random design of disector-counting frames. The counting
frame area was 2500 μm2 and the sampling grid area was 100 x 100 μm (Boger, et al.,
2006). The counting brick was approximately 20 μm thick after excluding the upper and
lower guard zones (2.5 μm each). The slides were coded and TH-ir cells were counted
using a 40x objective lens with a 1.4 numerical aperture. The selection of the first section
from the SN in the rostral position was random and every 3rd section was counted –
rendering a systematic random design. The total number of neurons was calculated.
Outline contours drawn for SN cell counts included areas containing predominately THlabeled dopaminergic neurons (SNc and lateralis). The SNr – containing mostly TH
fibers – was excluded. The cell size was measured on every 3rd section through the SN
in all 24 groups on the same sections used for stereological assessment (randomly
measuring at least 150 neurons per brain across all stereological sections) according to
previous protocols (Boger, et al., 2006; Boger, et al., 2007; Zaman, et al., 2008).

GDNF Protein Quantification (ELISA)
GDNF protein quantification was conducted at the Medical University of South
Carolina by Heather Boger, Ph.D. Protein levels were assessed using a commercially
available assay kit from Promega (Madison, WI) and a standard protocol (Albeck, et al.,
2003). Animals used in electrochemical recordings were euthanized (under deep
urethane anesthesia) and brains were dissected. The overlying cortex was peeled away
from coronal sections and the entire striatum was dissected including the medial and
lateral striatum but excluding the nucleus accumbens. Flat-bottom plates were coated
with the corresponding capture antibody, which binds the soluble captured neurotrophin.
The captured neurotrophin was bound by a second specific antibody, which was
detected using a species-specific antibody conjugated to horseradish peroxidase as a
tertiary reactant. Unbound conjugates were removed by subsequent wash steps
according to Promega protocols. After an incubation period with chromagenic substrate,
color change was measured in an ELISA plate reader at 450 nm. According to the assay
kit the quantification range for GDNF was 7.8–500 pg/mL and cross reactivity with other
trophic proteins ranged < 2–3%. Protein levels of GDNF were expressed as pg/mg wet
weight of tissue.
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Data Analysis and Statistics
Outliers > 2 standard deviations from the mean were removed from all data.
Statistical significance was defined as p < 0.05 for all analyses. In reported statistics, n
represents the number of animals unless indicated otherwise.

Results

GDNF Protein Levels
To quantify effective increases in GDNF protein after striatal treatment, ELISA
was used to determine protein levels in the striatum of GDNF- and vehicle-treated
Gdnf+/- and WT mice (n = 4) (Figure 5.1 B). There was a significant effect of GDNF
treatment [F3,12 = 17.46, p = 0.0001] determined by one-way ANOVA. Bonferroni post
hoc tests show vehicle-treated Gdnf+/- and WT mice had significant differences in protein
levels [mean ± SEM (pg/mg wet tissue weight), WT: 10.7 ± 0.60, Gdnf+/-: 6.8 ± 0.66, **p
< 0.01]. There was also a significant difference in protein levels after treatment in Gdnf+/mice [mean ± SEM (pg/mg wet tissue weight), vehicle: 6.8 ± 0.66, GDNF: 9.5 ± 0.39, *p
< 0.05] without significant difference in protein between vehicle- and GDNF-treated WT
mice [p > 0.05]. GDNF treatment in Gdnf+/- mice restored striatal GDNF levels to those
detected in WT mice [p > 0.05 versus WT (vehicle)]. WT and Gdnf+/- mice treated with
GDNF had significantly different protein levels [mean ± SEM (pg/mg wet tissue weight,
WT: 12.3 ± 0.52, Gdnf+/-: 9.5 ± 0.39 *p < 0.05] as did GDNF-treated WT and vehicletreated Gdnf+/- mice [***p < 0.001].
Immunohistochemistry was used to determine GDNF levels in the SN after
striatal GDNF treatment (Figure 5.1 A). Qualitative treatment of the results showed an
increase in staining intensity after treatment with GDNF. Both genotypes exhibited
comparable staining levels after GDNF treatment. These data suggest that striatal
GDNF administration increased the supply of GDNF in the SN – indicating retrograde
transport of GDNF may occur.

Locomotor Activity
As we have shown previously (Littrell, et al., 2010), spontaneous locomotor
activity in Gdnf+/- mice (pre-treatment) is decreased (**p = 0.0022; t20 = 3.515, (n = 8))
(Figure 5.2). Spontaneous locomotor activity was measured in mice treated with GDNF
(n = WT: 5 Gdnf+/-: 7) or vehicle (n = WT: 4-5 Gdnf+/-: 7) and analyzed using a 2
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(genotype) x 2 (treatment) x 4 (intervals) mixed-factor ANOVA with repeated measures
on the interval. Analysis shows a significant genotype x treatment interaction (F1,79=
5.114, p = 0.0265) as well as a significant treatment x time interaction (F3,79 = 9.255, p <
0.0001) (Figure 5.2). Additionally, there was a significant main effect of GDNF treatment
(F1,79 = 71.096, p < 0.0001) with a general increase in locomotor activity in GDNF-treated
groups of both genotypes (weeks 1-4 in Gdnf+/- mice and weeks 1-3 in WT mice). There
was also a significant main effect of time (F3,79 = 32.315, p < 0.0001) with both genotypes
(GDNF-treated) demonstrating an initial increase in locomotor activity that declined over
the 4-week testing period.
Mice treated with GDNF (n = WT: 5 Gdnf+/-: 7) or vehicle (n = WT: 4 Gdnf+/-: 7)
were tested for stimulated motor activity following nomifensine (4-weeks after GDNF
treatment). Data were analyzed using a genotype x treatment 1 (GDNF/vehicle) x
treatment 2 (nomifensine/saline) three-way ANOVA. As we have previously shown
(Littrell, et al., 2010), the administration of nomifensine increased locomotor activity in
both genotypes treated with GDNF or vehicle compared to saline administration (F1,38=
158.057, p < 0.0001).

There was a significant interaction between treatment 1

(GDNF/vehicle) and treatment 2 (nomifensine/saline) (F1,38 = 4.263, p = 0.0458) with
GDNF-treated groups showing a greater response to nomifensine in both genotypes
(Figure 5.2). These data suggest a synergistic effect of combining GDNF treatment with
nomifensine to increase locomotor activity.
Tyrosine Hydroxylase Immunohistochemistry
The number of DA neurons (TH-positive neurons) was determined in Gdnf+/- (n =
6) and WT (n = 4) mice after GDNF treatment (Figure 5.3 A). Four weeks after striatal
GDNF administration there was a significant effect of treatment on the number of DA
neurons in the SN [F3,16 = 31.70 p < 0.0001, one-way ANOVA (Figure 5.3 B)]. Bonferroni
post hoc analysis indicates Gdnf+/- mice had fewer TH-positive neurons compared to WT
mice (both vehicle-treated) [mean ± SEM, number of neurons; WT: 4209 ± 150; Gdnf+/-:
2841 ± 104; ***p < 0.001] as determined previously (Boger, et al., 2006). There was also
a significant increase in the number of TH-positive neurons after GDNF treatment in
Gdnf+/- mice [mean ± SEM, number of neurons; Vehicle: 2841 ± 104, GDNF: 3852 ± 132;
***p < 0.001] but no significant difference in TH-positive neurons between treatments in
WT mice [p > 0.05]. There was a significant difference between genotypes treated with
GDNF [mean ± SEM, number of neurons; WT: 4600 ± 171; Gdnf+/-: 3852 ± 132; **p <
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0.001] and a significant difference between WT mice treated with GDNF and Gdnf+/- mice
treated with vehicle [***p < 0.001].
Dopamine Release – Electrochemical Studies
Evoked DA release by local application of high-potassium solution was
determined for WT and Gdnf+/- mice after striatal treatment with GDNF (Figure 5.4). Data
were analyzed using two-tailed unpaired t tests to compare treatment effects within
genotypes. A significant decrease (*p = 0.0196, t11 = 2.73) in release amplitude after
GDNF treatment was apparent in the dorsal striatum of the rostral-medial recording site
in WT mice [Figure 5.4A, mean ± SEM (μM); Vehicle: 0.78 ± 0.28 (n = 3), GDNF: 0.26 ±
0.071 (n = 10), n represents the number of peaks].
Tissue Neurochemical Content
Neurochemical content was investigated to determine if there were changes in
tissue levels of DA or DA-metabolites: DOPAC and HVA. Neurochemical levels were
analyzed using a two-tailed unpaired t test comparing treatment groups within genotypes
for rostral (AP+1) and caudal (AP+0.1) brain sections (Table 5.1). Two samples were
obtained from each brain section in each animal. In rostral sections, there was as a
significant increase in DA content in non-littermate/non-transgenic C57/BL6 mice treated
with GDNF [*p = 0.0183]. In caudal sections, there was a significant increase in DOPAC
in WT mice treated with GDNF [*p = 0.016] and C57/BL6 mice treated with GDNF [*p =
0.0386].

Discussion

GDNF Protein Levels are Increased by Striatal GDNF Treatment
Delivery of GDNF to the striatum of Gdnf+/- mice led to an increase (40%) in
striatal GDNF protein levels compared to vehicle-treated Gdnf+/- mice (4-weeks after
treatment). A comparable difference in GDNF protein was not seen in treated WT mice,
although there was an increase (statistically insignificant) in GDNF protein. It is unknown
how processing or clearance of exogenous GDNF may be altered in Gdnf+/- mice. It is
possible that a higher dose of GDNF is necessary to result in detectable changes in WT
mice, which do not demonstrate protein reductions (Boger, et al., 2006). There was also
a significant difference in GDNF-treated WT and Gdnf+/- mice with more GDNF protein in
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WT mice. Thus, treatment with GDNF led to an increase in striatal protein only in Gdnf+/mice. The effective striatal protein levels were comparable to WT (vehicle) animals but
did not reach levels equivalent to that seen in GDNF-treated WT mice. Thus, protein
levels in GDNF-treated Gdnf+/- mice were restored to levels comparable to WT
counterparts (p > 0.05). A significant reduction (36%) in GDNF protein in the vehicletreated Gdnf+/- mice compared to vehicle-treated WT mice corroborates previous reports
of protein reductions in naïve Gdnf+/- mice (Boger, et al., 2006). Qualitative TH-ir
histological studies suggest that striatal GDNF treatment increased staining intensity of
GDNF in the SN of both WT and Gdnf+/- mice. Expression of GDNF is highest in the
developing striatum (Stromberg, et al., 1993), however, retrograde transport to the SN
(Barroso-Chinea, et al., 2005) is suggested to play a critical role in activation of the nigral
localized GDNF receptor - GFRα1 (Quartu, et al., 2007). Indeed, retrograde transport of
GDNF by striatal DA terminals has been demonstrated previously in animal models –
occurring within 24 hours after striatal delivery (Ai, et al., 2003; Lapchak, et al., 1997b).
In these studies retrograde transport processes are suggested by the increase in GDNFstaining intensity in the SN. Although increased receptor activation in the SN after GDNF
treatment is likely, this possibility requires further investigation.
Locomotor Behavior Enhanced by GDNF Treatment
As shown previously Gdnf+/- mice demonstrated reduced basal locomotor activity
and enhanced sensitivity to nomifensine-stimulated locomotor activity compared to WT
counterparts (Boger, et al., 2006; Littrell, et al., 2010) (see Nomifensine-Induced
Locomotor Activity). Treatment with GDNF increased spontaneous locomotor activity in
both genotypes, an effect that appears to diminish over time. Gdnf+/- mice displayed a
more sustained increase in activity with greater activity than WT mice (also treated with
GDNF) at 3- and 4-weeks. Importantly, these studies show that GDNF treatment can
restore behavioral deficits in middle-aged Gdnf+/- mice to comparable activity levels as
WT counterparts. It is hypothesized that Gdnf+/- mice demonstrate increased sensitivity
to GDNF treatment due to chronic GDNF depletion and compensatory increases in
GFRα1-receptor expression – a finding demonstrated in aged rats (Pruett and Salvatore,
2010). Because changes in GFRα1-receptor expression have been correlated with TH-ir
(Pruett and Salvatore, 2010), GFRα1-receptor expression has been suggested to
regulate nigral DA tissue content. Thus, changes in DA availability may also contribute to
the enhancing effects of GDNF, which are sustained in Gdnf+/- mice.
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The nomifensine-induced increase in locomotor activity was seen in all
genotypes and treatment groups and is consistent with the known pharmacological and
behavioral effects of the DAT inhibitor (Altar and Marshall, 1988). Sensitivity to
nomifensine was increased in GDNF-treated groups of both genotypes compared to
vehicle-treated groups of the same genotype. This enhanced effect may be attributed to
increased DA-neuron function in GDNF-treated groups as stated above. Indeed both
genotypes showed increased TH-ir (See Tyrosine Hydroxylase Immunohistochemistry)
that may result in increased: DA content, DA-receptor activation and motor activity
(Hebert and Gerhardt, 1997; Hebert, et al., 1996). The enhanced activity in GDNFtreated Gdnf+/- mice versus GDNF-treated WT mice may be due to increased DA
receptors (Kelly, et al., 1998) (see Striatal Dopamine D2-receptor mRNA and Protein
Expression) or compensatory increases in sensitivity to GDNF through upregulation of
GFRα1 receptors as discussed above.
We expected these behavioral findings to be accompanied with increases in DA
and DA-metabolite neurochemical levels as shown in previous studies using GDNF in
rats (Hebert and Gerhardt, 1997; Hebert, et al., 1996). However, the neurochemical
studies are not in agreement with behavioral measures. We believe the disagreement
with neurochemical studies is due to factors described below (see GDNF Treatment
Increases Neurochemical Levels in C57/Bl6 Mice and Non-Transgenic WT Mice). It is
possible that the increased TH-ir in the SN does not cause neurochemical changes at
striatal terminals. Alternatively, DA and DA-metabolite neurochemistry may be enhanced
at the cell bodies in the SN only. Nigral neurochemical effects and somatodendritic
receptor modulation have also been correlated with improved behavioral measures
(Bergquist, et al., 2003) and GDNF treatment (Hebert and Gerhardt, 1997; Hebert, et al.,
1996; Hoffer, et al., 1994). Although neurochemical levels were not directly determined
in the SN, the increase in TH-ir staining in the SN supports this hypothesis.
GDNF Treatment Increased Tyrosine Hydroxylase Staining
Consistent with prior studies establishing histological differences between
genotypes (Boger, et al., 2006), there was a decrease (48%) in number of TH-positive
neurons in vehicle-treated Gdnf+/- mice versus vehicle-treated WT mice. Treatment with
GDNF increased (36%) the number of TH-positive neurons in the SN of Gdnf+/- mice
compared to vehicle treated Gdnf+/- mice. While the number of TH-positive neurons is
substantially lower than GDNF-treated WT mice, GDNF-treated Gdnf+/- mice appear to
97

demonstrate equivalent values compared with WT (vehicle) mice. Thus, GDNF
treatment in Gdnf+/- mice restored the number of TH-positive neurons to comparable
levels as vehicle-treated WT counterparts (p > 0.05). The increase in TH-positive
neurons supports increased nigrostriatal DA-neuron function, which we would expect to
be accompanied with enhanced neurochemical levels and accompanying behavioral
improvements. Although an increase in staining of TH – the rate-limiting enzyme in DA
synthesis – is encouraging, investigation of other aspects of TH activity and DA-neuron
function are necessary to more clearly determine the effect(s) of GDNF treatment. Of
note, GDNF treatment has been shown to increase TH levels without concomitant
increases in DA neurochemical levels (Yang, et al., 2009). The phosphorylation state of
TH may also determine effective changes in neurochemical levels and has been shown
to be modulated by GDNF (Salvatore, et al., 2004; Yang, et al., 2009). It is currently
unclear if the TH-ir increase is a result of increased numbers of TH-positive neurons or
upregulation of TH expression, both of which may be modulated by GDNF and GDNFreceptor presence/activation (Cao, et al., 2010; Pruett and Salvatore, 2010).
Interestingly, GDNF-treated WT mice did not demonstrate increased TH-positive
neurons versus vehicle-treated WT counterparts (p > 0.05). Although enhancement of
some DA neurochemical levels has been reported in the intact nigrostriatal pathway of
young (Hebert, et al., 1996) and aged rodents (Hebert and Gerhardt, 1997), prior animal
studies investigating TH-ir after GDNF treatment have yielded inconsistent results. A
decrease in TH-ir after GDNF delivery to the intact nigrostriatal pathway of the rat
(Rosenblad, et al., 2003) has been reported, but another study in the aged primate
reported an increase in number of TH-positive neurons after GDNF delivery (Palfi, et al.,
2002). It has been proposed that GDNF treatment causes a transient phenotypic shift –
evident by an initial downregulation of TH. In parkinsonian rats (6-OHDA striatal
lesioned) treated with GDNF, an initial decline in TH-ir has been demonstrated with a
delayed increase in TH-positive neurons (8 weeks after GDNF treatment (Cohen, et al.,
2011)). Although the current studies were modeled after in vivo studies that addressed
similar neurochemical and behavioral parameters in the aged rat (Hebert and Gerhardt,
1997), it is possible that the effect of GDNF on TH may require a longer time course than
examined here. The time course may affect the results seen in both genotypes. The
effect on TH may develop later for WT mice and be more pronounced in Gdnf+/- mice at
later time points. Comparison of parkinsonian rats and the current mice studies presents
with confounding factors i.e. ongoing neurodegeneration in striatal lesion models, which
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implicates both neuro-restorative and -protective mechanisms (Sauer and Oertel, 1994).
We postulate that Gdnf+/- mice, demonstrating a chronic GDNF depletion, may be more
sensitive to GDNF supplementation due to a compensatory increase in surface
expression of GDNF receptors (Kozlowski, et al., 2004; Pruett and Salvatore, 2010) or
other mechanisms, which require further investigation.
Generally, the TH studies mirror results from GDNF protein quantification (see
GDNF Protein Levels). Specifically, no significant differences in protein levels were seen
between GDNF-treated WT and vehicle-treated WT mice. Again, it may be necessary to
increase the treatment dose to detect significant changes in protein levels and TH-ir in
WT mice because WT mice do not demonstrate deficits in GDNF protein or TH-ir.
GDNF Treatment Decreased Dopamine Release
The validity of DA signals obtained from electrochemical studies has been
questioned due to the dramatic difference in release amplitude values from previous
studies in naïve animals of the same age and genotypes (see Studies of Dopamine
Release). Due to these initial observations, non-littermate C57/BL6 mice (see Delivery of
GDNF) were also used in electrochemical studies, which failed to produce appropriate
signals for analysis (data not shown). Because observations in naïve mice show greater
striatal DA release than in the current studies, it is suspected that injection of GDNF into
the striatum may interfere with this recording technique. Thus, discussion of the findings
of DA release should be considered with these important caveats.
Interestingly, GDNF treatment significantly (67%) decreased evoked DA release
in the dorsal striatum of WT mice. Dopamine-receptor agonists have been shown to
positively influence GDNF expression (Ohta, et al., 2003). It is possible that GDNF also
modulates DA release – effectively modulating DA-receptor activation. Thus, GDNF
supplementation in WT mice may cause a downregulation of DA release. The decreased
release does not appear to be accompanied with changes in TH because WT mice did
not demonstrate any detectable differences in TH-ir in the SN, although there may be
changes in TH activity (Salvatore, et al., 2004) that are not apparent in these
histochemical analyses. Analysis of whole tissue neurochemical levels is discussed
below (see GDNF Treatment Increases Neurochemical Levels in C57/Bl6 mice and Nontransgenic WT Mice). This finding demonstrates a differential response to GDNF in WT
versus Gdnf+/- counterparts with the latter lacking detectable differences in DA release
after GDNF treatment. Compensatory changes in GDNF-receptor expression in Gdnf+/99

mice are expected and may contribute to the differential release findings – causing a
dose-response shift between Gdnf+/- and WT mice.
GDNF Treatment Increases Neurochemical Levels in C57/Bl6 Mice and NonTransgenic WT Mice
Based on prior studies showing heterogeneous function of DA terminals in the
dorsal and ventral striatum of Gdnf+/- mice, striatal sections were subdivided into dorsal
and ventral samples for HPLC-EC analysis of neurochemical content. The resulting
samples were below the ideal size (weight) to determine neurochemical levels (personal
communication, Wayne Cass, Ph.D.) The following neurochemical findings should be
considered with this caveat.
Dopamine neurochemical content in the anterior striatum was significantly
increased (63%) after GDNF treatment in non-littermate C57/BL6 mice. In the posterior
striatum, DOPAC levels were increased in GDNF-treated C57/BL6 mice (41%) as well
as GDNF-treated WT mice (56%). A lack of effect on DA neurochemistry in either striatal
section in Gdnf+/- mice is surprising because of the increase in TH-ir in the SN. We would
expect changes in TH to cause increases in DA or DA-metabolite levels. Additionally,
WT mice, which did not demonstrate increased TH staining intensity, did demonstrate
increased striatal DA and DOPAC levels. The relationships among GDNF, TH
expression and neurochemical levels have not been clearly determined. Some studies
have shown decreased TH expression without parallel changes in neurochemical
content with GDNF treatment (Rosenblad, et al., 2003).
Consideration of incongruent histological and neurochemical findings (GDNF
Treatment Increased Tyrosine Hydroxylase Staining) leads us to believe that the small
sample size (weight) was a major interfering factor in accurately determining tissue
weight and neurochemical content. Therefore, the calculation of neurochemical levels
(ng/g gram wet weight of tissue) is likely inaccurate.
Conclusions
Long-term changes in nigrostriatal DA-neuron function related to GDNF depletion
are suspected due to the critical role of GDNF in developmental processes (Granholm,
et al., 2000; Stromberg, et al., 1993). These studies further investigated the functional
abnormalities of DA neurons and behavioral deficits, which appear to be responsive to
trophic factor supplementation. Furthermore, sensitivity to trophic factor treatment
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appears to be influenced by a chronic and partial GDNF depletion with WT and Gdnf+/mice demonstrating altered responses to equivalent doses of GDNF. Altogether, these
studies suggest that regulation of endogenous trophic factors contributes to ageassociated dysfunction of the nigrostriatal pathway and behavioral impairments and
these deficits are potential targets for trophic factor treatment.

Copyright © Ofelia Meagan Littrell 2011
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Chapter Five: Figures
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Figure 5.1 GDNF Protein in the Substantia Nigra and Striatum
Tissue sections through the SN were stained for GDNF-ir (4 weeks after striatal
treatment of GDNF or vehicle). Representative sections show increased staining
intensity for GDNF in both genotypes treated with GDNF versus vehicle treatment (A).
GDNF protein levels were quantified by ELISA in striatal tissues (B). GDNF protein
levels in the striatum were averaged within genotypes of each treatment group. Vehicletreated Gdnf+/- mice had decreased GDNF protein levels versus vehicle-treated WT (**p
< 0.01) and GDNF-treated WT (***p < 0.001) mice. There was significant increase in
GDNF protein in Gdnf+/- mice treated with GDNF versus vehicle (*p < 0.05). In addition,
GDNF-treated Gdnf+/- mice demonstrated decreased GDNF protein levels compared to
GDNF-treated WT mice (*p < 0.05). Data are shown as mean ± SEM.
analyzed by a one-way ANOVA with Bonferroni’s post hoc tests.
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Figure 5.2 Spontaneous and Nomifensine-induced Locomotor Activity in GDNF-treated
+/Gdnf and WT Mice
Total distance traveled was measured prior to treatment and weekly after striatal
treatment with GDNF or vehicle. Spontaneous motor activity was measured at all time
points. Stimulated motor activity following nomifensine (7.5 mg/kg i.p.) was measured 4weeks after treatment. Pre-treatment locomotor activity was analyzed using a two-tailed
unpaired t test. Gdnf+/- mice displayed a significant decrease (**p = 0.0022; t20 = 3.515)
in locomotor activity versus WT mice. Spontaneous locomotor activity following
treatment was analyzed using a 2 (genotype) x 2 (treatment) x 4 (intervals) mixed-factor
ANOVA with repeated measures. There was a significant effect of GDNF treatment (F1,79
= 71.096, p < 0.0001) with greater locomotor activity in GDNF-treated groups. There was
also a significant effect of time (F3,79 = 32.315, p < 0.0001) with both GDNF-treated
genotypes exhibiting an increase in locomotor activity after treatment, which diminished
over the 4-week testing period. There were also significant interactions: genotype x
treatment (F1,79= 5.114, p = 0.0265) and treatment x time (F3,
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= 9.255, p < 0.0001).

Nomifensine-stimulated locomotor activity data was analyzed using a genotype x
103

treatment 1 (GDNF/vehicle) x treatment 2 (nomifensine/saline) three-way ANOVA. There
was a significant effect of GDNF treatment (F1,38 = 6.764, p = 0.0132) with greater
stimulated activity in GDNF-treated groups than vehicle-treated groups of both
genotypes. There was a significant effect of nomifensine (F1,38= 158.057, p < 0.0001)
with greater activity following nomifensine compared to saline (spontaneous locomotor
activity at 4 weeks) in all genotypes and treatment groups. Additionally, there was a
significant

interaction

between

treatment

1

(GDNF/vehicle)

and

treatment

2

(nomifensine/saline) (F1,38 = 4.263, p = 0.0458) with GDNF-treated groups showing a
greater response to nomifensine (both genotypes). All data are shown as mean ± SEM.
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Figure 5.3 Tyrosine Hydroxylase Immunoreactivity (TH-ir) in the Substantia Nigra
Tissue sections through the SN were stained for TH-ir (4 weeks after striatal treatment
with GDNF or vehicle). Representative sections (A) show increased numbers of THpositive neurons and increased fiber density in both genotypes treated with GDNF
versus vehicle treatment. The number of TH-positive neurons in the SN was averaged
for treatment groups of each genotype (B). Gdnf+/- (vehicle) mice had fewer TH-positive
neurons versus WT (vehicle) (***p < 0.001) and WT (GDNF treated) (***p < 0.001) mice.
There was a significant increase in number of neurons in Gdnf+/- mice treated with GDNF
(***p < 0.001, versus vehicle). Additionally, GDNF-treated Gdnf+/- mice had fewer THpositive neurons compared to GDNF-treated WT mice (**p < 0.01). Data are shown as
mean ± SEM. Data were analyzed by a one-way ANOVA with Bonferroni’s post hoc
tests.
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Figure 5.4 Amplitude of Evoked-Dopamine Signals in GDNF-treated Gdnf+/- Mice
A potassium chloride solution (120 mM) was applied locally (75-150 nL) in order to
measure DA release in the striatum (4-weeks after striatal treatment with GDNF or
vehicle). The resulting amplitude from striatal sub-regions was averaged and analyzed to
compare treatment groups. In the rostral-medial recording site (A) there was a significant
(*p = 0.0196) decrease in release amplitude in the dorsal striatum of WT mice. In the
caudal-lateral recording site (B) there were no significant changes (p > 0.05) in DA
release after GDNF treatment for either Gdnf+/- or WT mice. Data are shown as mean ±
SEM and were analyzed by a two-tailed unpaired t test comparing treatment of like
genotypes within striatal sub-regions.
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Table 5.1 Tissue Neurochemical Content after Treatment with GDNF

Data shown as mean ± SEM (ng/g wet weight of tissue). Analyzed by a two-tailed unpaired t test comparing
treatment groups within genotypes and striatal regions.
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Chapter Six: Final Conclusions
These studies highlight the potential of GDNF and similar molecules to modulate
DA-neuron function (Cowen and Gavazzi, 1998). The current findings are relevant to the
neurodegenerative processes involved in PD as well as brain aging (McGeer, et al.,
1988; Volkow, et al., 1998b). The ability of the nigrostriatal pathway to combat
neurodegenerative processes is highlighted by the requirement of a severe loss of DA
innervation to manifest motor impairment in Parkinson’s disease (Bernheimer, et al.,
1973). Thus, the nigrostriatal pathway exhibits a high degree of plasticity and
compensatory capacity that can be exploited by trophic factor supplementation
(Peterson and Nutt, 2008). Although there is conflicting evidence regarding the definitive
role of GDNF in aging, Parkinson’s disease and experimental models of DA-neuron
injury (Backman, et al., 2006; Jenner and Olanow, 1998; Nakajima, et al., 2001; Smith,
et al., 2003), these studies provide support for the importance of endogenous GDNF in
brain function. Finally, supplementation with trophic factors and/or phenotypic-mimetic
peptides (e.g. DNSPs) is a favorable approach for the treatment of nigrostriatal
dysfunction.
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